Page last updated: 2024-11-13

acp-196

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

acalabrutinib: inhibits Bruton’s tyrosine kinase; has antineoplastic activity [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

acalabrutinib : A member of the class of imidazopyrazines that is imidazo[1,5-a]pyrazine substituted by 4-(pyridin-2-ylcarbamoyl)phenyl, (2S)-1-(but-2-ynoyl)pyrrolidin-2-yl, and amino groups at positions 1, 3 and 8, respectively. It is an irreversible second-generation Bruton's tyrosine kinase (BTK) inhibitor that is approved by the FDA for the treatment of adult patients with mantle cell lymphoma (MCL) who have received at least one prior therapy. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID71226662
CHEMBL ID3707348
CHEBI ID167707
SCHEMBL ID14637368
MeSH IDM000614545

Synonyms (65)

Synonym
4-[8-amino-3-[(2s)-1-but-2-ynoylpyrrolidin-2-yl]imidazo[1,5-a]pyrazin-1-yl]-n-(2-pyridyl)benzamide
acp-196
acalabrutinibum
4-{8-amino-3-[(2s)-1-(but-2-ynoyl)pyrrolidin-2-yl]imidazo[1,5-a]pyrazin-1-yl}-n-(pyridin-2-yl)benzamide
1420477-60-6
(s)-4-(8-amino-3-(1-(but-2-ynoyl)pyrrolidin-2-yl)imidazo[1,5-a]pyrazin-1-yl)-n-(pyridin-2-yl)benzamide
CHEBI:167707 ,
acalabrutinib
bdbm50175583
S8116
(s)-4-(8-amino-3-(1-but-2-ynoylpyrrolidin-2-yl)imidazo[1,5-a]pyrazin-1-yl)-n-(pyridin-2-yl)benzamide
WDENQIQQYWYTPO-IBGZPJMESA-N
SCHEMBL14637368
CS-5356
HY-17600
CHEMBL3707348
benzamide, 4-[8-amino-3-[(2s)-1-(1-oxo-2-butyn-1-yl)-2-pyrrolidinyl]imidazo[1,5-a]pyrazin-1-yl]-n-2-pyridinyl-
acalabrutinib [usan:inn]
unii-i42748elqw
acalabrutinib [usan]
acalabrutinib [who-dd]
acalabrutinib [mi]
1639823-20-3
acalabrutinib [jan]
I42748ELQW ,
acalabrutinib [inn]
acalabrutinib [orange book]
benzamide, 4-(8-amino-3-((2s)-1-(1-oxo-2-butyn-1-yl)-2-pyrrolidinyl)imidazo(1,5-a)pyrazin-1-yl)-n-2-pyridinyl-
example 6 [us20140155385 a1]
4-[8-amino-3-[(2s)-1-but-2-ynoylpyrrolidin-2-yl]imidazo[1,5-a]pyrazin-1-yl]-n-pyridin-2-ylbenzamide
gtpl8912
J-690166
D10893
acp-196;acalabrutinib
EX-A881
calquence (tn)
acalabrutinib (jan/usan/inn)
AKOS030526094
mfcd29472294
NCGC00479074-01
acalabrutinib(acp196)
DB11703
DS-3326
acalabrutinib (acp-196)
acp 196
Q23668732
AMY5290
4-[8-amino-3-[(2s)-1-(1-oxo-2-butyn-1-yl)-2-pyrrolidinyl]imidazo[1,5-a]pyrazin-1-yl]-n-2-pyridinyl-benzamide
CCG-269407
(s)-4-(8-amino-3-(1-(but-2-ynoyl)pyrrolidin-2-yl)imidazo[1,5-a]pyrazin-1-yl)-n-(pyridin-2-yl)benzamide;acalabrutinib
A857446
nsc800976
nsc-800976
nsc-791164
nsc791164
DTXSID401026209
4-(8-amino-3-((2s)-1-(but-2-ynoyl)pyrrolidin-2-yl)imidazo(1,5-a)pyrazin-1-yl)-n-(pyridin-2-yl)benzamide
l01xe51
example 6 (us20140155385 a1)
4-(8-amino-3-((2s)-1-but-2-ynoylpyrrolidin-2-yl)imidazo(1,5-a)pyrazin-1-yl)-n-(2-pyridyl)benzamide
bruton tyrosine kinase inhibitor acp-196
(s)-4-(8-amino-3-(1-(but-2-ynoyl)pyrrolidin-2-yl)imidazo(1,5-a)pyrazin-1-yl)-n-(pyridin-2-yl)benzamide
EN300-7369651
acp196
Z2238902271

Research Excerpts

Toxicity

ExcerptReferenceRelevance
" With remarkable efficacy, good oral bioavailability, and modest adverse events profile, ibrutinib use is likely to continue to increase."( Ibrutinib in CLL: a focus on adverse events, resistance, and novel approaches beyond ibrutinib.
Kaur, V; Swami, A, 2017
)
0.46
" Outcomes assessed included overall response rate (ORR), complete response (CR) rate, overall survival (OS), progression-free survival (PFS), and adverse events."( Matching-adjusted Indirect Comparisons of the Efficacy and Safety of Acalabrutinib Versus Other Targeted Therapies in Relapsed/Refractory Mantle Cell Lymphoma.
Abhyankar, S; Kabadi, SM; Signorovitch, J; Song, J; Telford, C; Yao, Z; Zhao, J, 2019
)
0.51
" Treatment-related adverse events (AEs) can have a negative effect on treatment adherence."( Acalabrutinib: Managing Adverse Events and Improving Adherence in Patients With Mantle Cell Lymphoma.
Badillo, M; Chen, W; Guerrero, M; Nava, D; Rosa, M; Wang, M, 2020
)
0.56
" Treatment-related adverse events (AEs) occurred in 88% of patients (grade ≥3, 36%); the most common were headache (28%) and purpura (24%), both grade 1/2."( Safety and antitumor activity of acalabrutinib for relapsed/refractory B-cell malignancies: A Japanese phase I study.
Ando, K; Ennishi, D; Hayashi, N; Ichikawa, S; Iizumi, S; Izutsu, K; Kato, K; Kawasumi, H; Kumagai, K; Murayama, K; Nagai, H; Patel, P; Shibayama, H; Suzumiya, J; Yamamoto, K, 2021
)
0.62
" The most common adverse events (AEs) were headache (38%), diarrhea (37%), upper respiratory tract infection (22%), contusion (22%), nausea (22%), fatigue (21%), and cough (21%)."( Pooled analysis of safety data from clinical trials evaluating acalabrutinib monotherapy in mature B-cell malignancies.
Baek, M; Brown, JR; Byrd, JC; Chernyukhin, N; Christian, B; Dyer, MJS; Furman, RR; Ghia, P; Hamdy, AM; Hillmen, P; Izumi, R; Jurczak, W; Lezhava, T; O'Brien, SM; Owen, RG; Pagel, JM; Patel, P; Rule, S; Sharman, JP; Stephens, DM; Streetly, MJ; Sun, C; Wang, M, 2021
)
0.62
" This analysis characterizes pooled CV adverse events (AE) data in patients with CLL who received acalabrutinib monotherapy in clinical trials (clinicaltrials gov."( Cardiovascular adverse events in patients with chronic lymphocytic leukemia receiving acalabrutinib monotherapy: pooled analysis of 762 patients.
Brown, JR; Byrd, JC; Ferrajoli, A; Furman, RR; Ghia, P; Hillmen, P; Jurczak, W; Kuptsova-Clarkson, N; Moslehi, J; Pagel, JM; Patel, P; Sharman, JP; Stephens, DM; Sun, C; Tao, L, 2022
)
0.72
" Higher frequencies of grade 3-4 treatment-emergent adverse events (AE; 65% vs."( Safety and Efficacy of Pembrolizumab in Combination with Acalabrutinib in Advanced Head and Neck Squamous Cell Carcinoma: Phase 2 Proof-of-Concept Study.
Adkins, D; Algazi, A; Betts, CB; Cohen, EEW; Coussens, LM; Goldschmidt, JH; Guarino, MJ; Jimeno, A; Maloney, L; Munugalavadla, V; Nadler, E; Nemunaitis, J; Patel, P; Tao, L; Taylor, MH, 2022
)
0.72
" In summary, single oral dose of 50-mg acalabrutinib was safe and well tolerated in subjects with mild, moderate, and severe hepatic impairment and in healthy control subjects."( Evaluation of the Pharmacokinetics and Safety of a Single Dose of Acalabrutinib in Subjects With Hepatic Impairment.
Izumi, R; Kuo, H; Kwan, A; Madere, J; Marbury, T; Nguyen, H; Podoll, T; Preston, RA; Sharma, S; Slatter, JG; Smith, W; Vishwanathan, K; Ware, JA; Xu, Y, 2022
)
0.72
"Novel therapies improve clinical outcomes in chronic lymphocytic leukemia (CLL), although adverse event (AE) profiles differ."( Time and personnel costs associated with adverse event (AE) management among patients with chronic lymphocytic leukemia (CLL).
Castriota, F; Chang, R; DerSarkissian, M; Duh, MS; Gu, Y; Guo, H; Kunzweiler, C; Patel, H; Ryan, KJ; Wahlstrom, SK,
)
0.13
" Patients receiving A or A + O experienced significantly longer Q-TWiST versus C + O when toxicity was defined as grade 3-4 adverse events (AEs) (41."( Quality-adjusted survival time without symptoms or toxicity of acalabrutinib with or without obinutuzumab in patients with treatment-naive chronic lymphocytic leukemia.
Cai, L; Emeribe, U; Gaitonde, P; Liljas, B; Miranda, P; Roos, J; Sharman, JP,
)
0.13
"ELEVATE-RR demonstrated noninferior progression-free survival and lower incidence of key adverse events (AEs) with acalabrutinib vs ibrutinib in previously treated chronic lymphocytic leukemia."( Detailed safety profile of acalabrutinib vs ibrutinib in previously treated chronic lymphocytic leukemia in the ELEVATE-RR trial.
Bajwa, N; Brown, JR; Byrd, JC; Chanan-Khan, A; de Borja, M; Furman, RR; Ghia, P; Higgins, K; John, E; Jurczak, W; Kater, AP; Mato, A; Miranda, P; Munir, T; O'Brien, S; Seymour, JF; Stilgenbauer, S; Woyach, JA, 2023
)
0.91

Pharmacokinetics

ExcerptReferenceRelevance
" To elucidate on-target and pharmacodynamic effects of acalabrutinib, we evaluated several laboratory endpoints, including proteomic changes, chemokine modulation and impact on cell migration."( Pharmacodynamics and proteomic analysis of acalabrutinib therapy: similarity of on-target effects to ibrutinib and rationale for combination therapy.
Ayres, ML; Balakrishnan, K; Cheung, JP; Gandhi, V; Gay, J; Ivan, C; Keating, MJ; Lamothe, B; Marszalek, JR; Morse, J; Nelson, M; Patel, VK; Wierda, WG, 2018
)
0.48
" A physiologically-based pharmacokinetic (PBPK) model was developed for acalabrutinib and its active metabolite ACP-5862 to predict potential drug-drug interactions (DDIs)."( Evaluation of the Drug-Drug Interaction Potential of Acalabrutinib and Its Active Metabolite, ACP-5862, Using a Physiologically-Based Pharmacokinetic Modeling Approach.
Al-Huniti, N; Moorthy, G; Podoll, T; Slatter, JG; Vishwanathan, K; Ware, J; Xu, Y; Zhou, D, 2019
)
0.51
"To determine the pharmacodynamic relationship between target occupancy of Bruton tyrosine kinase (BTK) and inhibition of downstream signaling."( Pharmacodynamic Analysis of BTK Inhibition in Patients with Chronic Lymphocytic Leukemia Treated with Acalabrutinib.
Alsadhan, A; Bibikova, E; Cheung, J; Covey, T; Gaglione, EM; Gulrajani, M; Hamdy, A; Herman, SEM; Izumi, R; Nierman, P; Patel, P; Sun, C; Wiestner, A, 2020
)
0.56
"Patients with chronic lymphocytic leukemia (CLL) enrolled in a phase II clinical trial (NCT02337829) with the covalent, selective BTK inhibitor acalabrutinib donated blood samples for pharmacodynamic analyses."( Pharmacodynamic Analysis of BTK Inhibition in Patients with Chronic Lymphocytic Leukemia Treated with Acalabrutinib.
Alsadhan, A; Bibikova, E; Cheung, J; Covey, T; Gaglione, EM; Gulrajani, M; Hamdy, A; Herman, SEM; Izumi, R; Nierman, P; Patel, P; Sun, C; Wiestner, A, 2020
)
0.56
"In our present experiment, the aim of this paper was to develop and fully validate an accurate and simple ultra performance liquid chromatography tandem mass spectrometry (UPLC-MS/MS) assay for simultaneous quantification of acalabrutinib, ibrutinib, and their metabolites (ACP-5862 and PCI-45227) in beagle dog plasma and to survey the pharmacokinetic study of all analytes in beagle dogs."( Simultaneous measurement of acalabrutinib, ibrutinib, and their metabolites in beagle dog plasma by UPLC-MS/MS and its application to a pharmacokinetic study.
Jiang, Z; Lin, G; Shi, L; Wang, Y; Zhang, Y, 2020
)
0.56
" The pharmacokinetic and pharmacodynamic data of acalabrutinib were also discussed."( Assessing the pharmacokinetics of acalabrutinib in the treatment of chronic lymphocytic leukemia.
Li, J; Miao, Y; Xu, W, 2021
)
0.62
" A physiologically based pharmacokinetic (PBPK) model was developed based on the data of these studies."( Acalabrutinib CYP3A-mediated drug-drug interactions: Clinical evaluations and physiologically based pharmacokinetic modelling to inform dose adjustment strategy.
Chen, B; Cheung, J; Lai, R; Sarvaria, N; Sharma, S; Vishwanathan, K; Ware, J; Wei, H; Yotvat, M; Zhou, D; Zhou, L, 2022
)
0.72
" The aim of this study was to develop a physiologically based pharmacokinetic (PBPK) model to mechanistically describe absorption of immediate release capsule formulation of acalabrutinib in humans."( Physiologically Based Absorption Modelling to Explore the Formulation and Gastric pH Changes on the Pharmacokinetics of Acalabrutinib.
Chen, B; Pepin, X; Sharma, S; Tang, W; Zhou, D, 2023
)
0.91
"To develop a mathematical model combined between physiologically based pharmacokinetic and BTK occupancy (PBPK-BO) to simultaneously predict pharmacokinetic (PK) and pharmacodynamic (PD) changes of acalabrutinib (ACA) and active metabolite ACP-5862 in healthy humans as well as PD in patients."( Physiologically based pharmacokinetic combined BTK occupancy modeling for optimal dosing regimen prediction of acalabrutinib in patients alone, with different CYP3A4 variants, co-administered with CYP3A4 modulators and with hepatic impairment.
Liu, H; Liu, Y; Wang, G; Xu, L; Yi, B; Yu, S, 2022
)
0.72
" To evaluate and quantify the DDIs between them and provide rational dose management strategies of BTK inhibitors, we conducted this study using physiologically-based pharmacokinetic (PBPK) models."( Drug-drug interactions and dose management of BTK inhibitors when initiating nirmatrelvir/ritonavir (paxlovid) based on physiologically-based pharmacokinetic models.
Chen, L; Chen, W; Li, C; Li, L, 2023
)
0.91
"Physicochemical properties and pharmacokinetic parameters were acquired from the published literature and databases."( Drug-drug interactions and dose management of BTK inhibitors when initiating nirmatrelvir/ritonavir (paxlovid) based on physiologically-based pharmacokinetic models.
Chen, L; Chen, W; Li, C; Li, L, 2023
)
0.91

Compound-Compound Interactions

ExcerptReferenceRelevance
" A physiologically-based pharmacokinetic (PBPK) model was developed for acalabrutinib and its active metabolite ACP-5862 to predict potential drug-drug interactions (DDIs)."( Evaluation of the Drug-Drug Interaction Potential of Acalabrutinib and Its Active Metabolite, ACP-5862, Using a Physiologically-Based Pharmacokinetic Modeling Approach.
Al-Huniti, N; Moorthy, G; Podoll, T; Slatter, JG; Vishwanathan, K; Ware, J; Xu, Y; Zhou, D, 2019
)
0.51
" This study assessed the in vitro and in vivo functionality of CAR T cells transduced to express the anti-CD19 CAR of liso-cel in combination with ibrutinib or acalabrutinib."( Antitumor Potency of an Anti-CD19 Chimeric Antigen Receptor T-Cell Therapy, Lisocabtagene Maraleucel in Combination With Ibrutinib or Acalabrutinib.
Baturevych, A; Clouser, CR; Hause, RJ; Johnstone, TG; Jones, JC; Krejsa, CM; Ponce, R; Ports, MO; Qin, JS; Ragan, SP; Salmon, RA, 2020
)
0.56
" However, BTKi have a range of drug-drug and drug-food interactions, which may alter drug efficacy and/or increase toxicity."( Drug interactions with Bruton's tyrosine kinase inhibitors: clinical implications and management.
Fancher, KM; Pappacena, JJ, 2020
)
0.56
" These variants were subsequently combined with replacement of the cysteine 481 residue to which irreversible inhibitors, such as ibrutinib, acalabrutinib and zanubrutinib, bind."( BTK gatekeeper residue variation combined with cysteine 481 substitution causes super-resistance to irreversible inhibitors acalabrutinib, ibrutinib and zanubrutinib.
Berglöf, A; Estupiñán, HY; Mohammad, DK; Schaafsma, GCP; Shi, Y; Smith, CIE; Vihinen, M; Wang, Q; Yu, L; Zain, R; Zhou, L, 2021
)
0.62
" Herein, we investigated the effects of the two drugs on UDP-glucuronosyltransferase (UGT) activities to evaluate their potential risk for drug-drug interactions (DDIs) via UGT inhibition."( Comparison of the drug-drug interactions potential of ibrutinib and acalabrutinib via inhibition of UDP-glucuronosyltransferase.
Cao, J; Fan, X; Jiang, L; Liu, Y; Wang, X; Wang, Z; Xia, Y; Yan, M, 2021
)
0.62
"Patients received pembrolizumab 200 mg intravenously every 3 weeks, alone or in combination with acalabrutinib 100 mg orally twice daily."( Safety and Efficacy of Pembrolizumab in Combination with Acalabrutinib in Advanced Head and Neck Squamous Cell Carcinoma: Phase 2 Proof-of-Concept Study.
Adkins, D; Algazi, A; Betts, CB; Cohen, EEW; Coussens, LM; Goldschmidt, JH; Guarino, MJ; Jimeno, A; Maloney, L; Munugalavadla, V; Nadler, E; Nemunaitis, J; Patel, P; Tao, L; Taylor, MH, 2022
)
0.72
"Co-administration of Bruton's tyrosine kinase (BTK) inhibitors with nirmatrelvir/ritonavir is challenging because of potential drug-drug interactions (DDIs)."( Drug-drug interactions and dose management of BTK inhibitors when initiating nirmatrelvir/ritonavir (paxlovid) based on physiologically-based pharmacokinetic models.
Chen, L; Chen, W; Li, C; Li, L, 2023
)
0.91

Bioavailability

ExcerptReferenceRelevance
"Cell membrane permeability is an important determinant for oral absorption and bioavailability of a drug molecule."( Highly predictive and interpretable models for PAMPA permeability.
Jadhav, A; Kerns, E; Nguyen, K; Shah, P; Sun, H; Xu, X; Yan, Z; Yu, KR, 2017
)
0.46
"The ATP-binding cassette transporter P-glycoprotein (P-gp) is known to limit both brain penetration and oral bioavailability of many chemotherapy drugs."( A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
Ambudkar, SV; Brimacombe, KR; Chen, L; Gottesman, MM; Guha, R; Hall, MD; Klumpp-Thomas, C; Lee, OW; Lee, TD; Lusvarghi, S; Robey, RW; Shen, M; Tebase, BG, 2019
)
0.51
"The study assessed the relative bioavailability of an acalabrutinib suspension-in regular, degassed Coca-Cola-administered via NG tube (Acala-NG) versus the pharmacokinetics (PK) of an acalabrutinib capsule administered orally with water."( Bioavailability of acalabrutinib suspension delivered via nasogastric tube in the presence or absence of a proton pump inhibitor in healthy subjects.
Cheung, J; Gupta, A; Han, D; Majewski, M; Mann, J; Munugalavadla, V; Patel, P; Pepin, X; Sharma, S; Sheridan, L; Tomkinson, H; Townsley, D; Ware, JA; Wei, H; Zheng, L, 2022
)
0.72

Dosage Studied

ExcerptRelevanceReference
" PBPK dosing recommendations for DDIs should consider the magnitude of the parent drug excursion, relative to safe parent drug exposures, along with the excursion of total active components to best enable safe and adequate pharmacodynamic coverage."( Evaluation of the Drug-Drug Interaction Potential of Acalabrutinib and Its Active Metabolite, ACP-5862, Using a Physiologically-Based Pharmacokinetic Modeling Approach.
Al-Huniti, N; Moorthy, G; Podoll, T; Slatter, JG; Vishwanathan, K; Ware, J; Xu, Y; Zhou, D, 2019
)
0.51
" Acalabrutinib is an oral, highly selective BTK inhibitor that allows for twice-daily dosing due to its selectivity."( Acalabrutinib monotherapy in patients with relapsed/refractory chronic lymphocytic leukemia: updated phase 2 results.
Awan, FT; Barrientos, J; Brown, JR; Burke, K; Byrd, JC; Chaves, JM; Covey, T; Devereux, S; Frigault, MM; Furman, RR; Ghia, P; Gulrajani, M; Hamdy, A; Hillmen, P; Izumi, R; Martin, P; O'Brien, S; Pagel, JM; Patel, P; Rothbaum, W; Schuh, A; Stephens, DM; Wang, MH; Wierda, WG; Woyach, JA, 2020
)
0.56
"8) with BID dosing and an ORR of 79."( Clinical and biological implications of target occupancy in CLL treated with the BTK inhibitor acalabrutinib.
Ahn, IE; Cheung, J; Covey, T; Farooqui, MZH; Gaglione, EM; Gulrajani, M; Hamdy, A; Harris, HM; Herman, SEM; Izumi, R; Kendall, EK; Maric, I; Nierman, P; Patel, P; Pittaluga, S; Pleyer, C; Stetler-Stevenson, M; Sun, C; Wang, MH; Wiestner, A; Yuan, CM, 2020
)
0.56
" However, none of the investigated covariates led to clinically meaningful changes in exposure, supporting a flat dosing of acalabrutinib."( Improved characterization of the pharmacokinetics of acalabrutinib and its pharmacologically active metabolite, ACP-5862, in patients with B-cell malignancies and in healthy subjects using a population pharmacokinetic approach.
Bellanti, F; Buil-Bruna, N; Edlund, H; Liu, H; Sharma, S; Tomkinson, H; Vishwanathan, K; Ware, J, 2022
)
0.72
" Acalabrutinib monotherapy was given orally at 100 mg twice daily for cycle 1, then combined for six cycles with intravenous obinutuzumab (100 mg on cycle 2 day 1, 900 mg on day 2, 1000 mg on day 8, and 1000 mg on day 15 and on day 1 of cycles 3-7); and from the beginning of cycle 4, oral venetoclax was dosed daily using an accelerated ramp-up from 20 mg on day 1 to 400 mg by day 22 and continued at this dose thereafter."( Acalabrutinib, venetoclax, and obinutuzumab as frontline treatment for chronic lymphocytic leukaemia: a single-arm, open-label, phase 2 study.
Armand, P; Arnason, JE; Brown, JR; Crombie, JL; Davids, MS; Fisher, DC; Jacobson, CA; Kim, AI; LaCasce, AS; Lampson, BL; Lowney, JC; Montegaard, J; Ng, SY; Patterson, V; Pazienza, S; Tyekucheva, S; Wang, Z; Weinstock, M, 2021
)
0.62
" Next, to use the PBPK-BO to determine the optimal dosing regimens in patients alone, with different CYP3A4 variants, when co-administration with four CYP3A4 modulators and in patients with hepatic impairment, respectively."( Physiologically based pharmacokinetic combined BTK occupancy modeling for optimal dosing regimen prediction of acalabrutinib in patients alone, with different CYP3A4 variants, co-administered with CYP3A4 modulators and with hepatic impairment.
Liu, H; Liu, Y; Wang, G; Xu, L; Yi, B; Yu, S, 2022
)
0.72
" Finally, the model was applied to determine optimal dosing regimens in various clinical situations."( Physiologically based pharmacokinetic combined BTK occupancy modeling for optimal dosing regimen prediction of acalabrutinib in patients alone, with different CYP3A4 variants, co-administered with CYP3A4 modulators and with hepatic impairment.
Liu, H; Liu, Y; Wang, G; Xu, L; Yi, B; Yu, S, 2022
)
0.72
"The simulations demonstrated that 100 mg ACA twice daily (BID) was the optimal dosing regimen in patients alone."( Physiologically based pharmacokinetic combined BTK occupancy modeling for optimal dosing regimen prediction of acalabrutinib in patients alone, with different CYP3A4 variants, co-administered with CYP3A4 modulators and with hepatic impairment.
Liu, H; Liu, Y; Wang, G; Xu, L; Yi, B; Yu, S, 2022
)
0.72
"This PBPK-BO model can predict PK and PD in healthy humans and patients and also predict the optimal dosing regimens in various clinical situations."( Physiologically based pharmacokinetic combined BTK occupancy modeling for optimal dosing regimen prediction of acalabrutinib in patients alone, with different CYP3A4 variants, co-administered with CYP3A4 modulators and with hepatic impairment.
Liu, H; Liu, Y; Wang, G; Xu, L; Yi, B; Yu, S, 2022
)
0.72
" Using standard dosing (375 mg/m2) of rituximab causes loss of target membrane CD20 cells and exhaustion of the finite cytotoxic capacity of the innate immune system."( Acalabrutinib and high-frequency low-dose subcutaneous rituximab for initial therapy of chronic lymphocytic leukemia.
Baran, AM; Barr, PM; Casulo, C; Friedberg, JW; Reagan, PM; Rice, G; Wallace, DS; Zent, CS, 2023
)
0.91
"Acalabrutinib maleate tablets correspond to an improved formulation compared to acalabrutinib capsules as they can be dosed with and without acid reducing agents and therefore benefit more cancer patients."( Acalabrutinib Maleate Tablets: The Physiologically Based Biopharmaceutics Model behind the Drug Product Dissolution Specification.
Mann, J; McAlpine, V; Moir, A; Pepin, X, 2023
)
0.91
" The prospective simulations not only provided scientific evidence regarding rational dosing management strategies when initiating nirmatrelvir/ritonavir therapy but also provided a reference for the design of clinical DDIs study that may save resources and time."( Drug-drug interactions and dose management of BTK inhibitors when initiating nirmatrelvir/ritonavir (paxlovid) based on physiologically-based pharmacokinetic models.
Chen, L; Chen, W; Li, C; Li, L, 2023
)
0.91
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (3)

RoleDescription
EC 2.7.10.2 (non-specific protein-tyrosine kinase) inhibitorAn EC 2.7.10.* (protein-tyrosine kinase) inhibitor that specifically blocks the action of non-specific protein-tyrosine kinase (EC 2.7.10.2).
antineoplastic agentA substance that inhibits or prevents the proliferation of neoplasms.
apoptosis inducerAny substance that induces the process of apoptosis (programmed cell death) in multi-celled organisms.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (8)

ClassDescription
secondary carboxamideA carboxamide resulting from the formal condensation of a carboxylic acid with a primary amine; formula RC(=O)NHR(1).
benzamides
pyridinesAny organonitrogen heterocyclic compound based on a pyridine skeleton and its substituted derivatives.
aromatic amineAn amino compound in which the amino group is linked directly to an aromatic system.
pyrrolidinecarboxamide
imidazopyrazine
ynoneAn alpha,beta-unsaturated ketone of general formula R(1)C#C-C(=O)R(2) (R(2) =/= H) in which the aldehydic C=O function is conjugated to a C#C triple bond at the alpha,beta position.
tertiary carboxamideA carboxamide resulting from the formal condensation of a carboxylic acid with a secondary amine; formula RC(=O)NHR(1)R(2).
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (12)

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Epidermal growth factor receptorHomo sapiens (human)IC50 (µMol)1.87830.00000.536910.0000AID1538771; AID1720509; AID1781999; AID1880138
Receptor tyrosine-protein kinase erbB-2Homo sapiens (human)IC50 (µMol)1.00000.00010.545310.0000AID1720526; AID1913678
Tyrosine-protein kinase TecHomo sapiens (human)IC50 (µMol)0.08270.00050.06310.4720AID1720522; AID1880136; AID1913692
Tyrosine-protein kinase TXKHomo sapiens (human)IC50 (µMol)0.36800.00030.08210.4720AID1720525; AID1913693
Tyrosine-protein kinase BlkHomo sapiens (human)IC50 (µMol)1.00000.00010.43575.4700AID1720538
Cytoplasmic tyrosine-protein kinase BMXHomo sapiens (human)IC50 (µMol)0.23000.00040.23362.6650AID1720523; AID1781997; AID1913694
Tyrosine-protein kinase JAK3Homo sapiens (human)IC50 (µMol)1.00000.00010.41937.9200AID1720528
Synaptic vesicular amine transporterRattus norvegicus (Norway rat)IC50 (µMol)0.00310.00100.01460.1000AID1304232
Tyrosine-protein kinase BTKHomo sapiens (human)IC50 (µMol)0.10980.00010.25577.6000AID1304232; AID1357747; AID1468772; AID1468826; AID1557598; AID1560795; AID1560796; AID1560797; AID1560882; AID1720521; AID1781996; AID1853204; AID1880135; AID1913093
Tyrosine-protein kinase ITK/TSKHomo sapiens (human)IC50 (µMol)10.66670.00100.30905.6500AID1720524; AID1781998; AID1880137
Receptor tyrosine-protein kinase erbB-4Homo sapiens (human)IC50 (µMol)0.01600.00010.17362.5900AID1720527; AID1913680
Platelet glycoprotein VIHomo sapiens (human)IC50 (µMol)1.21000.00201.55884.0000AID1692287
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Activation Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Epidermal growth factor receptorHomo sapiens (human)EC50 (µMol)2.85000.00200.99027.9300AID1720530; AID1880140
Epidermal growth factor receptorHomo sapiens (human)Kd2.88500.00011.351420.8270AID1560826; AID1878118
Receptor tyrosine-protein kinase erbB-2Homo sapiens (human)Kd0.17870.00081.29315.1000AID1560827; AID1878102
Tyrosine-protein kinase TecHomo sapiens (human)Kd0.00980.00101.00958.7000AID1560824; AID1878121
Tyrosine-protein kinase TXKHomo sapiens (human)Kd0.02400.00061.91966.0000AID1878122
Tyrosine-protein kinase BlkHomo sapiens (human)Kd0.01800.00020.82287.9000AID1878115
Cytoplasmic tyrosine-protein kinase BMXHomo sapiens (human)Kd0.31450.00141.54897.4000AID1560823; AID1878116
Tyrosine-protein kinase JAK3Homo sapiens (human)Kd6.50000.00021.06888.7000AID1560829; AID1878120
Tyrosine-protein kinase BTKHomo sapiens (human)EC50 (µMol)0.05460.00580.20200.4750AID1880139; AID1912680
Tyrosine-protein kinase BTKHomo sapiens (human)Kd0.01180.00061.529910.1530AID1560822; AID1878117
Tyrosine-protein kinase ITK/TSKHomo sapiens (human)Kd11.00000.01300.86005.6000AID1560825; AID1878119
Receptor tyrosine-protein kinase erbB-4Homo sapiens (human)Kd0.10000.00091.25487.0000AID1560828; AID1878104
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (220)

Processvia Protein(s)Taxonomy
cell surface receptor signaling pathwayEpidermal growth factor receptorHomo sapiens (human)
epidermal growth factor receptor signaling pathwayEpidermal growth factor receptorHomo sapiens (human)
positive regulation of cell population proliferationEpidermal growth factor receptorHomo sapiens (human)
MAPK cascadeEpidermal growth factor receptorHomo sapiens (human)
ossificationEpidermal growth factor receptorHomo sapiens (human)
embryonic placenta developmentEpidermal growth factor receptorHomo sapiens (human)
positive regulation of protein phosphorylationEpidermal growth factor receptorHomo sapiens (human)
hair follicle developmentEpidermal growth factor receptorHomo sapiens (human)
translationEpidermal growth factor receptorHomo sapiens (human)
signal transductionEpidermal growth factor receptorHomo sapiens (human)
epidermal growth factor receptor signaling pathwayEpidermal growth factor receptorHomo sapiens (human)
activation of phospholipase C activityEpidermal growth factor receptorHomo sapiens (human)
salivary gland morphogenesisEpidermal growth factor receptorHomo sapiens (human)
midgut developmentEpidermal growth factor receptorHomo sapiens (human)
learning or memoryEpidermal growth factor receptorHomo sapiens (human)
circadian rhythmEpidermal growth factor receptorHomo sapiens (human)
positive regulation of cell population proliferationEpidermal growth factor receptorHomo sapiens (human)
diterpenoid metabolic processEpidermal growth factor receptorHomo sapiens (human)
peptidyl-tyrosine phosphorylationEpidermal growth factor receptorHomo sapiens (human)
cerebral cortex cell migrationEpidermal growth factor receptorHomo sapiens (human)
positive regulation of cell growthEpidermal growth factor receptorHomo sapiens (human)
lung developmentEpidermal growth factor receptorHomo sapiens (human)
positive regulation of cell migrationEpidermal growth factor receptorHomo sapiens (human)
positive regulation of superoxide anion generationEpidermal growth factor receptorHomo sapiens (human)
positive regulation of peptidyl-serine phosphorylationEpidermal growth factor receptorHomo sapiens (human)
response to cobalaminEpidermal growth factor receptorHomo sapiens (human)
response to hydroxyisoflavoneEpidermal growth factor receptorHomo sapiens (human)
cellular response to reactive oxygen speciesEpidermal growth factor receptorHomo sapiens (human)
peptidyl-tyrosine autophosphorylationEpidermal growth factor receptorHomo sapiens (human)
ERBB2-EGFR signaling pathwayEpidermal growth factor receptorHomo sapiens (human)
negative regulation of epidermal growth factor receptor signaling pathwayEpidermal growth factor receptorHomo sapiens (human)
negative regulation of protein catabolic processEpidermal growth factor receptorHomo sapiens (human)
vasodilationEpidermal growth factor receptorHomo sapiens (human)
positive regulation of phosphorylationEpidermal growth factor receptorHomo sapiens (human)
ovulation cycleEpidermal growth factor receptorHomo sapiens (human)
hydrogen peroxide metabolic processEpidermal growth factor receptorHomo sapiens (human)
negative regulation of apoptotic processEpidermal growth factor receptorHomo sapiens (human)
positive regulation of MAP kinase activityEpidermal growth factor receptorHomo sapiens (human)
tongue developmentEpidermal growth factor receptorHomo sapiens (human)
positive regulation of cyclin-dependent protein serine/threonine kinase activityEpidermal growth factor receptorHomo sapiens (human)
positive regulation of DNA repairEpidermal growth factor receptorHomo sapiens (human)
positive regulation of DNA replicationEpidermal growth factor receptorHomo sapiens (human)
positive regulation of bone resorptionEpidermal growth factor receptorHomo sapiens (human)
positive regulation of DNA-templated transcriptionEpidermal growth factor receptorHomo sapiens (human)
positive regulation of vasoconstrictionEpidermal growth factor receptorHomo sapiens (human)
negative regulation of mitotic cell cycleEpidermal growth factor receptorHomo sapiens (human)
positive regulation of transcription by RNA polymerase IIEpidermal growth factor receptorHomo sapiens (human)
regulation of JNK cascadeEpidermal growth factor receptorHomo sapiens (human)
symbiont entry into host cellEpidermal growth factor receptorHomo sapiens (human)
protein autophosphorylationEpidermal growth factor receptorHomo sapiens (human)
astrocyte activationEpidermal growth factor receptorHomo sapiens (human)
positive regulation of fibroblast proliferationEpidermal growth factor receptorHomo sapiens (human)
digestive tract morphogenesisEpidermal growth factor receptorHomo sapiens (human)
positive regulation of smooth muscle cell proliferationEpidermal growth factor receptorHomo sapiens (human)
neuron projection morphogenesisEpidermal growth factor receptorHomo sapiens (human)
epithelial cell proliferationEpidermal growth factor receptorHomo sapiens (human)
positive regulation of epithelial cell proliferationEpidermal growth factor receptorHomo sapiens (human)
regulation of peptidyl-tyrosine phosphorylationEpidermal growth factor receptorHomo sapiens (human)
protein insertion into membraneEpidermal growth factor receptorHomo sapiens (human)
response to calcium ionEpidermal growth factor receptorHomo sapiens (human)
regulation of phosphatidylinositol 3-kinase/protein kinase B signal transductionEpidermal growth factor receptorHomo sapiens (human)
positive regulation of phosphatidylinositol 3-kinase/protein kinase B signal transductionEpidermal growth factor receptorHomo sapiens (human)
positive regulation of synaptic transmission, glutamatergicEpidermal growth factor receptorHomo sapiens (human)
positive regulation of glial cell proliferationEpidermal growth factor receptorHomo sapiens (human)
morphogenesis of an epithelial foldEpidermal growth factor receptorHomo sapiens (human)
eyelid development in camera-type eyeEpidermal growth factor receptorHomo sapiens (human)
response to UV-AEpidermal growth factor receptorHomo sapiens (human)
positive regulation of mucus secretionEpidermal growth factor receptorHomo sapiens (human)
regulation of ERK1 and ERK2 cascadeEpidermal growth factor receptorHomo sapiens (human)
positive regulation of ERK1 and ERK2 cascadeEpidermal growth factor receptorHomo sapiens (human)
cellular response to amino acid stimulusEpidermal growth factor receptorHomo sapiens (human)
cellular response to mechanical stimulusEpidermal growth factor receptorHomo sapiens (human)
cellular response to cadmium ionEpidermal growth factor receptorHomo sapiens (human)
cellular response to epidermal growth factor stimulusEpidermal growth factor receptorHomo sapiens (human)
cellular response to estradiol stimulusEpidermal growth factor receptorHomo sapiens (human)
cellular response to xenobiotic stimulusEpidermal growth factor receptorHomo sapiens (human)
cellular response to dexamethasone stimulusEpidermal growth factor receptorHomo sapiens (human)
positive regulation of canonical Wnt signaling pathwayEpidermal growth factor receptorHomo sapiens (human)
liver regenerationEpidermal growth factor receptorHomo sapiens (human)
cell-cell adhesionEpidermal growth factor receptorHomo sapiens (human)
positive regulation of protein kinase C activityEpidermal growth factor receptorHomo sapiens (human)
positive regulation of G1/S transition of mitotic cell cycleEpidermal growth factor receptorHomo sapiens (human)
positive regulation of non-canonical NF-kappaB signal transductionEpidermal growth factor receptorHomo sapiens (human)
positive regulation of prolactin secretionEpidermal growth factor receptorHomo sapiens (human)
positive regulation of miRNA transcriptionEpidermal growth factor receptorHomo sapiens (human)
positive regulation of protein localization to plasma membraneEpidermal growth factor receptorHomo sapiens (human)
negative regulation of cardiocyte differentiationEpidermal growth factor receptorHomo sapiens (human)
neurogenesisEpidermal growth factor receptorHomo sapiens (human)
multicellular organism developmentEpidermal growth factor receptorHomo sapiens (human)
positive regulation of kinase activityEpidermal growth factor receptorHomo sapiens (human)
cell surface receptor protein tyrosine kinase signaling pathwayEpidermal growth factor receptorHomo sapiens (human)
cell surface receptor signaling pathwayReceptor tyrosine-protein kinase erbB-2Homo sapiens (human)
positive regulation of protein phosphorylationReceptor tyrosine-protein kinase erbB-2Homo sapiens (human)
protein phosphorylationReceptor tyrosine-protein kinase erbB-2Homo sapiens (human)
signal transductionReceptor tyrosine-protein kinase erbB-2Homo sapiens (human)
enzyme-linked receptor protein signaling pathwayReceptor tyrosine-protein kinase erbB-2Homo sapiens (human)
cell surface receptor protein tyrosine kinase signaling pathwayReceptor tyrosine-protein kinase erbB-2Homo sapiens (human)
heart developmentReceptor tyrosine-protein kinase erbB-2Homo sapiens (human)
neuromuscular junction developmentReceptor tyrosine-protein kinase erbB-2Homo sapiens (human)
motor neuron axon guidanceReceptor tyrosine-protein kinase erbB-2Homo sapiens (human)
Schwann cell developmentReceptor tyrosine-protein kinase erbB-2Homo sapiens (human)
peptidyl-tyrosine phosphorylationReceptor tyrosine-protein kinase erbB-2Homo sapiens (human)
positive regulation of cell growthReceptor tyrosine-protein kinase erbB-2Homo sapiens (human)
regulation of microtubule-based processReceptor tyrosine-protein kinase erbB-2Homo sapiens (human)
immature T cell proliferation in thymusReceptor tyrosine-protein kinase erbB-2Homo sapiens (human)
negative regulation of immature T cell proliferation in thymusReceptor tyrosine-protein kinase erbB-2Homo sapiens (human)
positive regulation of Rho protein signal transductionReceptor tyrosine-protein kinase erbB-2Homo sapiens (human)
intracellular signal transductionReceptor tyrosine-protein kinase erbB-2Homo sapiens (human)
ERBB2-ERBB3 signaling pathwayReceptor tyrosine-protein kinase erbB-2Homo sapiens (human)
ERBB2-EGFR signaling pathwayReceptor tyrosine-protein kinase erbB-2Homo sapiens (human)
ERBB2-ERBB4 signaling pathwayReceptor tyrosine-protein kinase erbB-2Homo sapiens (human)
wound healingReceptor tyrosine-protein kinase erbB-2Homo sapiens (human)
myelinationReceptor tyrosine-protein kinase erbB-2Homo sapiens (human)
positive regulation of MAP kinase activityReceptor tyrosine-protein kinase erbB-2Homo sapiens (human)
phosphatidylinositol 3-kinase/protein kinase B signal transductionReceptor tyrosine-protein kinase erbB-2Homo sapiens (human)
positive regulation of translationReceptor tyrosine-protein kinase erbB-2Homo sapiens (human)
regulation of angiogenesisReceptor tyrosine-protein kinase erbB-2Homo sapiens (human)
positive regulation of cell adhesionReceptor tyrosine-protein kinase erbB-2Homo sapiens (human)
positive regulation of transcription by RNA polymerase IReceptor tyrosine-protein kinase erbB-2Homo sapiens (human)
oligodendrocyte differentiationReceptor tyrosine-protein kinase erbB-2Homo sapiens (human)
positive regulation of epithelial cell proliferationReceptor tyrosine-protein kinase erbB-2Homo sapiens (human)
regulation of ERK1 and ERK2 cascadeReceptor tyrosine-protein kinase erbB-2Homo sapiens (human)
cellular response to growth factor stimulusReceptor tyrosine-protein kinase erbB-2Homo sapiens (human)
cellular response to epidermal growth factor stimulusReceptor tyrosine-protein kinase erbB-2Homo sapiens (human)
semaphorin-plexin signaling pathwayReceptor tyrosine-protein kinase erbB-2Homo sapiens (human)
positive regulation of protein targeting to membraneReceptor tyrosine-protein kinase erbB-2Homo sapiens (human)
neurotransmitter receptor localization to postsynaptic specialization membraneReceptor tyrosine-protein kinase erbB-2Homo sapiens (human)
neurogenesisReceptor tyrosine-protein kinase erbB-2Homo sapiens (human)
positive regulation of MAPK cascadeReceptor tyrosine-protein kinase erbB-2Homo sapiens (human)
negative regulation of apoptotic processReceptor tyrosine-protein kinase erbB-2Homo sapiens (human)
positive regulation of kinase activityReceptor tyrosine-protein kinase erbB-2Homo sapiens (human)
multicellular organism developmentReceptor tyrosine-protein kinase erbB-2Homo sapiens (human)
positive regulation of cell population proliferationReceptor tyrosine-protein kinase erbB-2Homo sapiens (human)
neuron differentiationReceptor tyrosine-protein kinase erbB-2Homo sapiens (human)
protein phosphorylationTyrosine-protein kinase TecHomo sapiens (human)
integrin-mediated signaling pathwayTyrosine-protein kinase TecHomo sapiens (human)
regulation of platelet activationTyrosine-protein kinase TecHomo sapiens (human)
intracellular signal transductionTyrosine-protein kinase TecHomo sapiens (human)
tissue regenerationTyrosine-protein kinase TecHomo sapiens (human)
B cell receptor signaling pathwayTyrosine-protein kinase TecHomo sapiens (human)
adaptive immune responseTyrosine-protein kinase TecHomo sapiens (human)
T cell receptor signaling pathwayTyrosine-protein kinase TecHomo sapiens (human)
positive regulation of cytokine productionTyrosine-protein kinase TXKHomo sapiens (human)
adaptive immune responseTyrosine-protein kinase TXKHomo sapiens (human)
protein phosphorylationTyrosine-protein kinase TXKHomo sapiens (human)
activation of phospholipase C activityTyrosine-protein kinase TXKHomo sapiens (human)
regulation of gene expressionTyrosine-protein kinase TXKHomo sapiens (human)
positive regulation of type II interferon productionTyrosine-protein kinase TXKHomo sapiens (human)
positive regulation of transcription by RNA polymerase IITyrosine-protein kinase TXKHomo sapiens (human)
protein autophosphorylationTyrosine-protein kinase TXKHomo sapiens (human)
T cell receptor signaling pathwayTyrosine-protein kinase TXKHomo sapiens (human)
positive regulation of type II interferon-mediated signaling pathwayTyrosine-protein kinase TXKHomo sapiens (human)
peptidyl-tyrosine phosphorylationTyrosine-protein kinase BlkHomo sapiens (human)
positive regulation of insulin secretionTyrosine-protein kinase BlkHomo sapiens (human)
positive regulation of protein bindingTyrosine-protein kinase BlkHomo sapiens (human)
intracellular signal transductionTyrosine-protein kinase BlkHomo sapiens (human)
B cell receptor signaling pathwayTyrosine-protein kinase BlkHomo sapiens (human)
innate immune responseTyrosine-protein kinase BlkHomo sapiens (human)
protein phosphorylationTyrosine-protein kinase BlkHomo sapiens (human)
cell differentiationTyrosine-protein kinase BlkHomo sapiens (human)
cell surface receptor protein tyrosine kinase signaling pathwayTyrosine-protein kinase BlkHomo sapiens (human)
protein phosphorylationCytoplasmic tyrosine-protein kinase BMXHomo sapiens (human)
phosphatidylinositol biosynthetic processCytoplasmic tyrosine-protein kinase BMXHomo sapiens (human)
apoptotic processCytoplasmic tyrosine-protein kinase BMXHomo sapiens (human)
cell adhesionCytoplasmic tyrosine-protein kinase BMXHomo sapiens (human)
signal transductionCytoplasmic tyrosine-protein kinase BMXHomo sapiens (human)
mesoderm developmentCytoplasmic tyrosine-protein kinase BMXHomo sapiens (human)
intracellular signal transductionCytoplasmic tyrosine-protein kinase BMXHomo sapiens (human)
protein autophosphorylationCytoplasmic tyrosine-protein kinase BMXHomo sapiens (human)
B cell receptor signaling pathwayCytoplasmic tyrosine-protein kinase BMXHomo sapiens (human)
adaptive immune responseCytoplasmic tyrosine-protein kinase BMXHomo sapiens (human)
adaptive immune responseTyrosine-protein kinase JAK3Homo sapiens (human)
negative regulation of dendritic cell cytokine productionTyrosine-protein kinase JAK3Homo sapiens (human)
protein phosphorylationTyrosine-protein kinase JAK3Homo sapiens (human)
enzyme-linked receptor protein signaling pathwayTyrosine-protein kinase JAK3Homo sapiens (human)
tyrosine phosphorylation of STAT proteinTyrosine-protein kinase JAK3Homo sapiens (human)
peptidyl-tyrosine phosphorylationTyrosine-protein kinase JAK3Homo sapiens (human)
B cell differentiationTyrosine-protein kinase JAK3Homo sapiens (human)
negative regulation of interleukin-10 productionTyrosine-protein kinase JAK3Homo sapiens (human)
negative regulation of interleukin-12 productionTyrosine-protein kinase JAK3Homo sapiens (human)
intracellular signal transductionTyrosine-protein kinase JAK3Homo sapiens (human)
interleukin-15-mediated signaling pathwayTyrosine-protein kinase JAK3Homo sapiens (human)
interleukin-4-mediated signaling pathwayTyrosine-protein kinase JAK3Homo sapiens (human)
interleukin-2-mediated signaling pathwayTyrosine-protein kinase JAK3Homo sapiens (human)
interleukin-9-mediated signaling pathwayTyrosine-protein kinase JAK3Homo sapiens (human)
T cell homeostasisTyrosine-protein kinase JAK3Homo sapiens (human)
innate immune responseTyrosine-protein kinase JAK3Homo sapiens (human)
negative regulation of FasL productionTyrosine-protein kinase JAK3Homo sapiens (human)
negative regulation of T-helper 1 cell differentiationTyrosine-protein kinase JAK3Homo sapiens (human)
regulation of receptor signaling pathway via JAK-STATTyrosine-protein kinase JAK3Homo sapiens (human)
negative regulation of T cell activationTyrosine-protein kinase JAK3Homo sapiens (human)
growth hormone receptor signaling pathway via JAK-STATTyrosine-protein kinase JAK3Homo sapiens (human)
regulation of T cell apoptotic processTyrosine-protein kinase JAK3Homo sapiens (human)
negative regulation of thymocyte apoptotic processTyrosine-protein kinase JAK3Homo sapiens (human)
response to interleukin-2Tyrosine-protein kinase JAK3Homo sapiens (human)
response to interleukin-4Tyrosine-protein kinase JAK3Homo sapiens (human)
response to interleukin-15Tyrosine-protein kinase JAK3Homo sapiens (human)
response to interleukin-9Tyrosine-protein kinase JAK3Homo sapiens (human)
regulation of apoptotic processTyrosine-protein kinase JAK3Homo sapiens (human)
cell differentiationTyrosine-protein kinase JAK3Homo sapiens (human)
cell surface receptor signaling pathway via JAK-STATTyrosine-protein kinase JAK3Homo sapiens (human)
cytokine-mediated signaling pathwayTyrosine-protein kinase JAK3Homo sapiens (human)
neutrophil homeostasisTyrosine-protein kinase BTKHomo sapiens (human)
positive regulation of type III hypersensitivityTyrosine-protein kinase BTKHomo sapiens (human)
positive regulation of type I hypersensitivityTyrosine-protein kinase BTKHomo sapiens (human)
adaptive immune responseTyrosine-protein kinase BTKHomo sapiens (human)
B cell affinity maturationTyrosine-protein kinase BTKHomo sapiens (human)
histamine secretion by mast cellTyrosine-protein kinase BTKHomo sapiens (human)
positive regulation of immunoglobulin productionTyrosine-protein kinase BTKHomo sapiens (human)
regulation of B cell cytokine productionTyrosine-protein kinase BTKHomo sapiens (human)
MyD88-dependent toll-like receptor signaling pathwayTyrosine-protein kinase BTKHomo sapiens (human)
regulation of B cell apoptotic processTyrosine-protein kinase BTKHomo sapiens (human)
protein phosphorylationTyrosine-protein kinase BTKHomo sapiens (human)
mesoderm developmentTyrosine-protein kinase BTKHomo sapiens (human)
peptidyl-tyrosine phosphorylationTyrosine-protein kinase BTKHomo sapiens (human)
calcium-mediated signalingTyrosine-protein kinase BTKHomo sapiens (human)
proteoglycan catabolic processTyrosine-protein kinase BTKHomo sapiens (human)
negative regulation of B cell proliferationTyrosine-protein kinase BTKHomo sapiens (human)
positive regulation of B cell proliferationTyrosine-protein kinase BTKHomo sapiens (human)
response to lipopolysaccharideTyrosine-protein kinase BTKHomo sapiens (human)
negative regulation of interleukin-10 productionTyrosine-protein kinase BTKHomo sapiens (human)
positive regulation of interleukin-6 productionTyrosine-protein kinase BTKHomo sapiens (human)
positive regulation of tumor necrosis factor productionTyrosine-protein kinase BTKHomo sapiens (human)
cellular response to reactive oxygen speciesTyrosine-protein kinase BTKHomo sapiens (human)
intracellular signal transductionTyrosine-protein kinase BTKHomo sapiens (human)
Fc-epsilon receptor signaling pathwayTyrosine-protein kinase BTKHomo sapiens (human)
B cell activationTyrosine-protein kinase BTKHomo sapiens (human)
innate immune responseTyrosine-protein kinase BTKHomo sapiens (human)
positive regulation of B cell differentiationTyrosine-protein kinase BTKHomo sapiens (human)
cell maturationTyrosine-protein kinase BTKHomo sapiens (human)
positive regulation of phagocytosisTyrosine-protein kinase BTKHomo sapiens (human)
B cell receptor signaling pathwayTyrosine-protein kinase BTKHomo sapiens (human)
positive regulation of NF-kappaB transcription factor activityTyrosine-protein kinase BTKHomo sapiens (human)
monocyte proliferationTyrosine-protein kinase BTKHomo sapiens (human)
cellular response to molecule of fungal originTyrosine-protein kinase BTKHomo sapiens (human)
apoptotic signaling pathwayTyrosine-protein kinase BTKHomo sapiens (human)
cellular response to interleukin-7Tyrosine-protein kinase BTKHomo sapiens (human)
positive regulation of interleukin-17A productionTyrosine-protein kinase BTKHomo sapiens (human)
positive regulation of NLRP3 inflammasome complex assemblyTyrosine-protein kinase BTKHomo sapiens (human)
positive regulation of synoviocyte proliferationTyrosine-protein kinase BTKHomo sapiens (human)
eosinophil homeostasisTyrosine-protein kinase BTKHomo sapiens (human)
T cell receptor signaling pathwayTyrosine-protein kinase BTKHomo sapiens (human)
positive regulation of cytokine productionTyrosine-protein kinase ITK/TSKHomo sapiens (human)
adaptive immune responseTyrosine-protein kinase ITK/TSKHomo sapiens (human)
cellular defense responseTyrosine-protein kinase ITK/TSKHomo sapiens (human)
signal transductionTyrosine-protein kinase ITK/TSKHomo sapiens (human)
activation of phospholipase C activityTyrosine-protein kinase ITK/TSKHomo sapiens (human)
intracellular signal transductionTyrosine-protein kinase ITK/TSKHomo sapiens (human)
T cell activationTyrosine-protein kinase ITK/TSKHomo sapiens (human)
gamma-delta T cell activationTyrosine-protein kinase ITK/TSKHomo sapiens (human)
T cell receptor signaling pathwayTyrosine-protein kinase ITK/TSKHomo sapiens (human)
protein phosphorylationTyrosine-protein kinase ITK/TSKHomo sapiens (human)
B cell receptor signaling pathwayTyrosine-protein kinase ITK/TSKHomo sapiens (human)
NK T cell differentiationTyrosine-protein kinase ITK/TSKHomo sapiens (human)
neural crest cell migrationReceptor tyrosine-protein kinase erbB-4Homo sapiens (human)
positive regulation of protein phosphorylationReceptor tyrosine-protein kinase erbB-4Homo sapiens (human)
signal transductionReceptor tyrosine-protein kinase erbB-4Homo sapiens (human)
cell surface receptor protein tyrosine kinase signaling pathwayReceptor tyrosine-protein kinase erbB-4Homo sapiens (human)
epidermal growth factor receptor signaling pathwayReceptor tyrosine-protein kinase erbB-4Homo sapiens (human)
cell surface receptor signaling pathway via JAK-STATReceptor tyrosine-protein kinase erbB-4Homo sapiens (human)
nervous system developmentReceptor tyrosine-protein kinase erbB-4Homo sapiens (human)
synapse assemblyReceptor tyrosine-protein kinase erbB-4Homo sapiens (human)
heart developmentReceptor tyrosine-protein kinase erbB-4Homo sapiens (human)
lactationReceptor tyrosine-protein kinase erbB-4Homo sapiens (human)
positive regulation of cell population proliferationReceptor tyrosine-protein kinase erbB-4Homo sapiens (human)
negative regulation of cell population proliferationReceptor tyrosine-protein kinase erbB-4Homo sapiens (human)
embryonic pattern specificationReceptor tyrosine-protein kinase erbB-4Homo sapiens (human)
cell migrationReceptor tyrosine-protein kinase erbB-4Homo sapiens (human)
peptidyl-tyrosine phosphorylationReceptor tyrosine-protein kinase erbB-4Homo sapiens (human)
central nervous system morphogenesisReceptor tyrosine-protein kinase erbB-4Homo sapiens (human)
olfactory bulb interneuron differentiationReceptor tyrosine-protein kinase erbB-4Homo sapiens (human)
regulation of cell migrationReceptor tyrosine-protein kinase erbB-4Homo sapiens (human)
ERBB4 signaling pathwayReceptor tyrosine-protein kinase erbB-4Homo sapiens (human)
ERBB2-ERBB4 signaling pathwayReceptor tyrosine-protein kinase erbB-4Homo sapiens (human)
ERBB4-ERBB4 signaling pathwayReceptor tyrosine-protein kinase erbB-4Homo sapiens (human)
positive regulation of tyrosine phosphorylation of STAT proteinReceptor tyrosine-protein kinase erbB-4Homo sapiens (human)
mitochondrial fragmentation involved in apoptotic processReceptor tyrosine-protein kinase erbB-4Homo sapiens (human)
cell fate commitmentReceptor tyrosine-protein kinase erbB-4Homo sapiens (human)
positive regulation of DNA-templated transcriptionReceptor tyrosine-protein kinase erbB-4Homo sapiens (human)
positive regulation of receptor signaling pathway via JAK-STATReceptor tyrosine-protein kinase erbB-4Homo sapiens (human)
protein autophosphorylationReceptor tyrosine-protein kinase erbB-4Homo sapiens (human)
positive regulation of phosphatidylinositol 3-kinase/protein kinase B signal transductionReceptor tyrosine-protein kinase erbB-4Homo sapiens (human)
positive regulation of cardiac muscle cell proliferationReceptor tyrosine-protein kinase erbB-4Homo sapiens (human)
mammary gland epithelial cell differentiationReceptor tyrosine-protein kinase erbB-4Homo sapiens (human)
mammary gland alveolus developmentReceptor tyrosine-protein kinase erbB-4Homo sapiens (human)
cardiac muscle tissue regenerationReceptor tyrosine-protein kinase erbB-4Homo sapiens (human)
positive regulation of ERK1 and ERK2 cascadeReceptor tyrosine-protein kinase erbB-4Homo sapiens (human)
cellular response to epidermal growth factor stimulusReceptor tyrosine-protein kinase erbB-4Homo sapiens (human)
establishment of planar polarity involved in nephron morphogenesisReceptor tyrosine-protein kinase erbB-4Homo sapiens (human)
neurotransmitter receptor localization to postsynaptic specialization membraneReceptor tyrosine-protein kinase erbB-4Homo sapiens (human)
positive regulation of protein localization to cell surfaceReceptor tyrosine-protein kinase erbB-4Homo sapiens (human)
negative regulation of apoptotic processReceptor tyrosine-protein kinase erbB-4Homo sapiens (human)
positive regulation of kinase activityReceptor tyrosine-protein kinase erbB-4Homo sapiens (human)
multicellular organism developmentReceptor tyrosine-protein kinase erbB-4Homo sapiens (human)
neurogenesisReceptor tyrosine-protein kinase erbB-4Homo sapiens (human)
positive regulation of platelet aggregationPlatelet glycoprotein VIHomo sapiens (human)
enzyme-linked receptor protein signaling pathwayPlatelet glycoprotein VIHomo sapiens (human)
platelet activationPlatelet glycoprotein VIHomo sapiens (human)
collagen-activated tyrosine kinase receptor signaling pathwayPlatelet glycoprotein VIHomo sapiens (human)
collagen-activated signaling pathwayPlatelet glycoprotein VIHomo sapiens (human)
platelet aggregationPlatelet glycoprotein VIHomo sapiens (human)
immune response-regulating signaling pathwayPlatelet glycoprotein VIHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (47)

Processvia Protein(s)Taxonomy
epidermal growth factor receptor activityEpidermal growth factor receptorHomo sapiens (human)
virus receptor activityEpidermal growth factor receptorHomo sapiens (human)
chromatin bindingEpidermal growth factor receptorHomo sapiens (human)
double-stranded DNA bindingEpidermal growth factor receptorHomo sapiens (human)
MAP kinase kinase kinase activityEpidermal growth factor receptorHomo sapiens (human)
protein tyrosine kinase activityEpidermal growth factor receptorHomo sapiens (human)
transmembrane receptor protein tyrosine kinase activityEpidermal growth factor receptorHomo sapiens (human)
transmembrane signaling receptor activityEpidermal growth factor receptorHomo sapiens (human)
epidermal growth factor receptor activityEpidermal growth factor receptorHomo sapiens (human)
integrin bindingEpidermal growth factor receptorHomo sapiens (human)
protein bindingEpidermal growth factor receptorHomo sapiens (human)
calmodulin bindingEpidermal growth factor receptorHomo sapiens (human)
ATP bindingEpidermal growth factor receptorHomo sapiens (human)
enzyme bindingEpidermal growth factor receptorHomo sapiens (human)
kinase bindingEpidermal growth factor receptorHomo sapiens (human)
protein kinase bindingEpidermal growth factor receptorHomo sapiens (human)
protein phosphatase bindingEpidermal growth factor receptorHomo sapiens (human)
protein tyrosine kinase activator activityEpidermal growth factor receptorHomo sapiens (human)
transmembrane receptor protein tyrosine kinase activator activityEpidermal growth factor receptorHomo sapiens (human)
ubiquitin protein ligase bindingEpidermal growth factor receptorHomo sapiens (human)
identical protein bindingEpidermal growth factor receptorHomo sapiens (human)
cadherin bindingEpidermal growth factor receptorHomo sapiens (human)
actin filament bindingEpidermal growth factor receptorHomo sapiens (human)
ATPase bindingEpidermal growth factor receptorHomo sapiens (human)
epidermal growth factor bindingEpidermal growth factor receptorHomo sapiens (human)
growth factor bindingReceptor tyrosine-protein kinase erbB-2Homo sapiens (human)
RNA polymerase I core bindingReceptor tyrosine-protein kinase erbB-2Homo sapiens (human)
protein tyrosine kinase activityReceptor tyrosine-protein kinase erbB-2Homo sapiens (human)
transmembrane receptor protein tyrosine kinase activityReceptor tyrosine-protein kinase erbB-2Homo sapiens (human)
transmembrane signaling receptor activityReceptor tyrosine-protein kinase erbB-2Homo sapiens (human)
signaling receptor bindingReceptor tyrosine-protein kinase erbB-2Homo sapiens (human)
protein bindingReceptor tyrosine-protein kinase erbB-2Homo sapiens (human)
ATP bindingReceptor tyrosine-protein kinase erbB-2Homo sapiens (human)
coreceptor activityReceptor tyrosine-protein kinase erbB-2Homo sapiens (human)
receptor tyrosine kinase bindingReceptor tyrosine-protein kinase erbB-2Homo sapiens (human)
identical protein bindingReceptor tyrosine-protein kinase erbB-2Homo sapiens (human)
ErbB-3 class receptor bindingReceptor tyrosine-protein kinase erbB-2Homo sapiens (human)
protein heterodimerization activityReceptor tyrosine-protein kinase erbB-2Homo sapiens (human)
non-membrane spanning protein tyrosine kinase activityTyrosine-protein kinase TecHomo sapiens (human)
protein bindingTyrosine-protein kinase TecHomo sapiens (human)
ATP bindingTyrosine-protein kinase TecHomo sapiens (human)
phospholipid bindingTyrosine-protein kinase TecHomo sapiens (human)
metal ion bindingTyrosine-protein kinase TecHomo sapiens (human)
protein bindingTyrosine-protein kinase TXKHomo sapiens (human)
ATP bindingTyrosine-protein kinase TXKHomo sapiens (human)
non-membrane spanning protein tyrosine kinase activityTyrosine-protein kinase TXKHomo sapiens (human)
protein tyrosine kinase activityTyrosine-protein kinase BlkHomo sapiens (human)
non-membrane spanning protein tyrosine kinase activityTyrosine-protein kinase BlkHomo sapiens (human)
protein bindingTyrosine-protein kinase BlkHomo sapiens (human)
ATP bindingTyrosine-protein kinase BlkHomo sapiens (human)
signaling receptor bindingTyrosine-protein kinase BlkHomo sapiens (human)
protein tyrosine kinase activityCytoplasmic tyrosine-protein kinase BMXHomo sapiens (human)
non-membrane spanning protein tyrosine kinase activityCytoplasmic tyrosine-protein kinase BMXHomo sapiens (human)
protein bindingCytoplasmic tyrosine-protein kinase BMXHomo sapiens (human)
ATP bindingCytoplasmic tyrosine-protein kinase BMXHomo sapiens (human)
metal ion bindingCytoplasmic tyrosine-protein kinase BMXHomo sapiens (human)
protein tyrosine kinase activityTyrosine-protein kinase JAK3Homo sapiens (human)
protein bindingTyrosine-protein kinase JAK3Homo sapiens (human)
ATP bindingTyrosine-protein kinase JAK3Homo sapiens (human)
protein phosphatase bindingTyrosine-protein kinase JAK3Homo sapiens (human)
growth hormone receptor bindingTyrosine-protein kinase JAK3Homo sapiens (human)
non-membrane spanning protein tyrosine kinase activityTyrosine-protein kinase JAK3Homo sapiens (human)
protein tyrosine kinase activityTyrosine-protein kinase BTKHomo sapiens (human)
non-membrane spanning protein tyrosine kinase activityTyrosine-protein kinase BTKHomo sapiens (human)
protein bindingTyrosine-protein kinase BTKHomo sapiens (human)
ATP bindingTyrosine-protein kinase BTKHomo sapiens (human)
phosphatidylinositol-3,4,5-trisphosphate bindingTyrosine-protein kinase BTKHomo sapiens (human)
phospholipase activator activityTyrosine-protein kinase BTKHomo sapiens (human)
identical protein bindingTyrosine-protein kinase BTKHomo sapiens (human)
phospholipase bindingTyrosine-protein kinase BTKHomo sapiens (human)
metal ion bindingTyrosine-protein kinase BTKHomo sapiens (human)
non-membrane spanning protein tyrosine kinase activityTyrosine-protein kinase ITK/TSKHomo sapiens (human)
protein bindingTyrosine-protein kinase ITK/TSKHomo sapiens (human)
ATP bindingTyrosine-protein kinase ITK/TSKHomo sapiens (human)
metal ion bindingTyrosine-protein kinase ITK/TSKHomo sapiens (human)
transcription cis-regulatory region bindingReceptor tyrosine-protein kinase erbB-4Homo sapiens (human)
protein tyrosine kinase activityReceptor tyrosine-protein kinase erbB-4Homo sapiens (human)
transmembrane receptor protein tyrosine kinase activityReceptor tyrosine-protein kinase erbB-4Homo sapiens (human)
epidermal growth factor receptor activityReceptor tyrosine-protein kinase erbB-4Homo sapiens (human)
epidermal growth factor receptor bindingReceptor tyrosine-protein kinase erbB-4Homo sapiens (human)
protein bindingReceptor tyrosine-protein kinase erbB-4Homo sapiens (human)
ATP bindingReceptor tyrosine-protein kinase erbB-4Homo sapiens (human)
neuregulin receptor activityReceptor tyrosine-protein kinase erbB-4Homo sapiens (human)
protein homodimerization activityReceptor tyrosine-protein kinase erbB-4Homo sapiens (human)
GABA receptor bindingReceptor tyrosine-protein kinase erbB-4Homo sapiens (human)
transmembrane signaling receptor activityPlatelet glycoprotein VIHomo sapiens (human)
protein bindingPlatelet glycoprotein VIHomo sapiens (human)
collagen bindingPlatelet glycoprotein VIHomo sapiens (human)
signaling receptor activityPlatelet glycoprotein VIHomo sapiens (human)
collagen receptor activityPlatelet glycoprotein VIHomo sapiens (human)
protein tyrosine kinase bindingPlatelet glycoprotein VIHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (49)

Processvia Protein(s)Taxonomy
endosomeEpidermal growth factor receptorHomo sapiens (human)
plasma membraneEpidermal growth factor receptorHomo sapiens (human)
ruffle membraneEpidermal growth factor receptorHomo sapiens (human)
Golgi membraneEpidermal growth factor receptorHomo sapiens (human)
extracellular spaceEpidermal growth factor receptorHomo sapiens (human)
nucleusEpidermal growth factor receptorHomo sapiens (human)
cytoplasmEpidermal growth factor receptorHomo sapiens (human)
endosomeEpidermal growth factor receptorHomo sapiens (human)
endoplasmic reticulum membraneEpidermal growth factor receptorHomo sapiens (human)
plasma membraneEpidermal growth factor receptorHomo sapiens (human)
focal adhesionEpidermal growth factor receptorHomo sapiens (human)
cell surfaceEpidermal growth factor receptorHomo sapiens (human)
endosome membraneEpidermal growth factor receptorHomo sapiens (human)
membraneEpidermal growth factor receptorHomo sapiens (human)
basolateral plasma membraneEpidermal growth factor receptorHomo sapiens (human)
apical plasma membraneEpidermal growth factor receptorHomo sapiens (human)
cell junctionEpidermal growth factor receptorHomo sapiens (human)
clathrin-coated endocytic vesicle membraneEpidermal growth factor receptorHomo sapiens (human)
early endosome membraneEpidermal growth factor receptorHomo sapiens (human)
nuclear membraneEpidermal growth factor receptorHomo sapiens (human)
membrane raftEpidermal growth factor receptorHomo sapiens (human)
perinuclear region of cytoplasmEpidermal growth factor receptorHomo sapiens (human)
multivesicular body, internal vesicle lumenEpidermal growth factor receptorHomo sapiens (human)
intracellular vesicleEpidermal growth factor receptorHomo sapiens (human)
protein-containing complexEpidermal growth factor receptorHomo sapiens (human)
receptor complexEpidermal growth factor receptorHomo sapiens (human)
Shc-EGFR complexEpidermal growth factor receptorHomo sapiens (human)
basal plasma membraneEpidermal growth factor receptorHomo sapiens (human)
semaphorin receptor complexReceptor tyrosine-protein kinase erbB-2Homo sapiens (human)
nucleusReceptor tyrosine-protein kinase erbB-2Homo sapiens (human)
nucleoplasmReceptor tyrosine-protein kinase erbB-2Homo sapiens (human)
early endosomeReceptor tyrosine-protein kinase erbB-2Homo sapiens (human)
cytosolReceptor tyrosine-protein kinase erbB-2Homo sapiens (human)
plasma membraneReceptor tyrosine-protein kinase erbB-2Homo sapiens (human)
endosome membraneReceptor tyrosine-protein kinase erbB-2Homo sapiens (human)
membraneReceptor tyrosine-protein kinase erbB-2Homo sapiens (human)
basolateral plasma membraneReceptor tyrosine-protein kinase erbB-2Homo sapiens (human)
apical plasma membraneReceptor tyrosine-protein kinase erbB-2Homo sapiens (human)
neuromuscular junctionReceptor tyrosine-protein kinase erbB-2Homo sapiens (human)
ruffle membraneReceptor tyrosine-protein kinase erbB-2Homo sapiens (human)
presynaptic membraneReceptor tyrosine-protein kinase erbB-2Homo sapiens (human)
myelin sheathReceptor tyrosine-protein kinase erbB-2Homo sapiens (human)
perinuclear region of cytoplasmReceptor tyrosine-protein kinase erbB-2Homo sapiens (human)
ERBB3:ERBB2 complexReceptor tyrosine-protein kinase erbB-2Homo sapiens (human)
receptor complexReceptor tyrosine-protein kinase erbB-2Homo sapiens (human)
plasma membraneReceptor tyrosine-protein kinase erbB-2Homo sapiens (human)
basal plasma membraneReceptor tyrosine-protein kinase erbB-2Homo sapiens (human)
cytosolTyrosine-protein kinase TecHomo sapiens (human)
cytoskeletonTyrosine-protein kinase TecHomo sapiens (human)
plasma membraneTyrosine-protein kinase TecHomo sapiens (human)
plasma membraneTyrosine-protein kinase TecHomo sapiens (human)
nucleusTyrosine-protein kinase TXKHomo sapiens (human)
nucleoplasmTyrosine-protein kinase TXKHomo sapiens (human)
nucleolusTyrosine-protein kinase TXKHomo sapiens (human)
cytoplasmTyrosine-protein kinase TXKHomo sapiens (human)
cytosolTyrosine-protein kinase TXKHomo sapiens (human)
plasma membraneTyrosine-protein kinase TXKHomo sapiens (human)
plasma membraneTyrosine-protein kinase TXKHomo sapiens (human)
cytosolTyrosine-protein kinase BlkHomo sapiens (human)
plasma membraneTyrosine-protein kinase BlkHomo sapiens (human)
nucleoplasmCytoplasmic tyrosine-protein kinase BMXHomo sapiens (human)
cytosolCytoplasmic tyrosine-protein kinase BMXHomo sapiens (human)
plasma membraneCytoplasmic tyrosine-protein kinase BMXHomo sapiens (human)
ruffle membraneCytoplasmic tyrosine-protein kinase BMXHomo sapiens (human)
plasma membraneCytoplasmic tyrosine-protein kinase BMXHomo sapiens (human)
extrinsic component of plasma membraneTyrosine-protein kinase JAK3Homo sapiens (human)
extrinsic component of cytoplasmic side of plasma membraneTyrosine-protein kinase JAK3Homo sapiens (human)
endosomeTyrosine-protein kinase JAK3Homo sapiens (human)
cytosolTyrosine-protein kinase JAK3Homo sapiens (human)
cytoskeletonTyrosine-protein kinase JAK3Homo sapiens (human)
plasma membraneTyrosine-protein kinase JAK3Homo sapiens (human)
cytosolTyrosine-protein kinase JAK3Homo sapiens (human)
nucleusTyrosine-protein kinase BTKHomo sapiens (human)
cytoplasmTyrosine-protein kinase BTKHomo sapiens (human)
cytosolTyrosine-protein kinase BTKHomo sapiens (human)
plasma membraneTyrosine-protein kinase BTKHomo sapiens (human)
cytoplasmic vesicleTyrosine-protein kinase BTKHomo sapiens (human)
membrane raftTyrosine-protein kinase BTKHomo sapiens (human)
perinuclear region of cytoplasmTyrosine-protein kinase BTKHomo sapiens (human)
plasma membraneTyrosine-protein kinase BTKHomo sapiens (human)
nucleusTyrosine-protein kinase ITK/TSKHomo sapiens (human)
cytosolTyrosine-protein kinase ITK/TSKHomo sapiens (human)
cell-cell junctionTyrosine-protein kinase ITK/TSKHomo sapiens (human)
plasma membraneTyrosine-protein kinase ITK/TSKHomo sapiens (human)
plasma membraneReceptor tyrosine-protein kinase erbB-4Homo sapiens (human)
extracellular regionReceptor tyrosine-protein kinase erbB-4Homo sapiens (human)
nucleusReceptor tyrosine-protein kinase erbB-4Homo sapiens (human)
nucleoplasmReceptor tyrosine-protein kinase erbB-4Homo sapiens (human)
mitochondrionReceptor tyrosine-protein kinase erbB-4Homo sapiens (human)
mitochondrial matrixReceptor tyrosine-protein kinase erbB-4Homo sapiens (human)
cytosolReceptor tyrosine-protein kinase erbB-4Homo sapiens (human)
plasma membraneReceptor tyrosine-protein kinase erbB-4Homo sapiens (human)
basolateral plasma membraneReceptor tyrosine-protein kinase erbB-4Homo sapiens (human)
neuromuscular junctionReceptor tyrosine-protein kinase erbB-4Homo sapiens (human)
presynaptic membraneReceptor tyrosine-protein kinase erbB-4Homo sapiens (human)
postsynaptic membraneReceptor tyrosine-protein kinase erbB-4Homo sapiens (human)
postsynaptic density membraneReceptor tyrosine-protein kinase erbB-4Homo sapiens (human)
glutamatergic synapseReceptor tyrosine-protein kinase erbB-4Homo sapiens (human)
GABA-ergic synapseReceptor tyrosine-protein kinase erbB-4Homo sapiens (human)
receptor complexReceptor tyrosine-protein kinase erbB-4Homo sapiens (human)
basal plasma membraneReceptor tyrosine-protein kinase erbB-4Homo sapiens (human)
membrane raftPlatelet glycoprotein VIHomo sapiens (human)
plasma membranePlatelet glycoprotein VIHomo sapiens (human)
cell surfacePlatelet glycoprotein VIHomo sapiens (human)
extracellular exosomePlatelet glycoprotein VIHomo sapiens (human)
tetraspanin-enriched microdomainPlatelet glycoprotein VIHomo sapiens (human)
plasma membranePlatelet glycoprotein VIHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (119)

Assay IDTitleYearJournalArticle
AID1347411qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS Mechanism Interrogation Plate v5.0 (MIPE) Libary2020ACS chemical biology, 07-17, Volume: 15, Issue:7
High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1346986P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1645848NCATS Kinetic Aqueous Solubility Profiling2019Bioorganic & medicinal chemistry, 07-15, Volume: 27, Issue:14
Predictive models of aqueous solubility of organic compounds built on A large dataset of high integrity.
AID1296008Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening2020SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1
Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening.
AID1347159Primary screen GU Rhodamine qHTS for Zika virus inhibitors: Unlinked NS2B-NS3 protease assay2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1508612NCATS Parallel Artificial Membrane Permeability Assay (PAMPA) Profiling2017Bioorganic & medicinal chemistry, 02-01, Volume: 25, Issue:3
Highly predictive and interpretable models for PAMPA permeability.
AID1346987P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1508591NCATS Rat Liver Microsome Stability Profiling2020Scientific reports, 11-26, Volume: 10, Issue:1
Retrospective assessment of rat liver microsomal stability at NCATS: data and QSAR models.
AID1347160Primary screen NINDS Rhodamine qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1880137Inhibition of ITK (unknown origin)2022Journal of medicinal chemistry, 04-28, Volume: 65, Issue:8
The Ascension of Targeted Covalent Inhibitors.
AID1720525Inhibition of recombinant human N-terminal GST-tagged TXK (260 to 527 residues) expressed in baculovirus expression system using tyrosine-6 peptide as substrate preincubated for 1 hr in presence of ATP by Z'-LYTE assay2020Bioorganic & medicinal chemistry letters, 07-15, Volume: 30, Issue:14
Discovery of quinoline-based irreversible BTK inhibitors.
AID1720520Glutathione reactivity in 50% MeOH in phosphate buffer pH 7.4 assessed as half life2020Bioorganic & medicinal chemistry letters, 07-15, Volume: 30, Issue:14
Discovery of quinoline-based irreversible BTK inhibitors.
AID1560830Selectivity ratio of Kd for DNA-tagged recombinant BMX (unknown origin) to Kd for DNA-tagged recombinant BTK (unknown origin)2020Journal of medicinal chemistry, 05-28, Volume: 63, Issue:10
Discovery of LOU064 (Remibrutinib), a Potent and Highly Selective Covalent Inhibitor of Bruton's Tyrosine Kinase.
AID1781978Receptor occupancy at BTK in spleen of ICR mouse at 15 mg/kg, po after 24 hrs by ELISA2021Journal of medicinal chemistry, 11-11, Volume: 64, Issue:21
Discovery of 1-Amino-1
AID1720528Inhibition of recombinant human GST-tagged JAK3 catalytic domain (781 to 1124 residues) expressed in baculovirus expression system using tyrosine-6 peptide as substrate preincubated for 1 hr in presence of ATP by Z'-LYTE assay2020Bioorganic & medicinal chemistry letters, 07-15, Volume: 30, Issue:14
Discovery of quinoline-based irreversible BTK inhibitors.
AID1538770Reversible inhibition of FAM-labeled peptide binding to full-length human N-terminal GST-tagged BTK C481S mutant (2 to 659 residues) expressed in baculovirus infected Sf21 insect cells preincubated for 10 mins followed by FAM-labeled peptide addition and 2019Journal of medicinal chemistry, 07-25, Volume: 62, Issue:14
Discovery of 4-Aminoquinoline-3-carboxamide Derivatives as Potent Reversible Bruton's Tyrosine Kinase Inhibitors for the Treatment of Rheumatoid Arthritis.
AID1878102Binding affinity to ERBB2 (unknown origin) assessed as dissociation constant by KINOMEscan analysis2022Bioorganic & medicinal chemistry letters, 03-15, Volume: 60Optimization of a novel piperazinone series as potent selective peripheral covalent BTK inhibitors.
AID1894679Antiproliferative activity against human TMD8 cells assessed as reduction in cell viability incubated for 72 hrs by CCK-8 assay2021European journal of medicinal chemistry, May-05, Volume: 217Emerging small-molecule inhibitors of the Bruton's tyrosine kinase (BTK): Current development.
AID1878119Binding affinity to ITK (unknown origin) assessed as dissociation constant by KINOMEscan analysis2022Bioorganic & medicinal chemistry letters, 03-15, Volume: 60Optimization of a novel piperazinone series as potent selective peripheral covalent BTK inhibitors.
AID1468826Inhibition of BTK in human whole blood derived-basophils assessed as suppression of IgE mediated-FcepsilonR ligation-stimulated CD63 expression2018Journal of medicinal chemistry, 03-22, Volume: 61, Issue:6
Discovery of GDC-0853: A Potent, Selective, and Noncovalent Bruton's Tyrosine Kinase Inhibitor in Early Clinical Development.
AID1782012Antiproliferative activity against human Ramos cells assessed as reduction in cell viability incubated for 72 hrs by celltiter-glo assay2021Journal of medicinal chemistry, 11-11, Volume: 64, Issue:21
Discovery of 1-Amino-1
AID1468809Inhibition of recombinant human cytoplasmic GST-tagged ERBB4 expressed in baculovirus at 1 uM by Z'-LYTE assay2018Journal of medicinal chemistry, 03-22, Volume: 61, Issue:6
Discovery of GDC-0853: A Potent, Selective, and Noncovalent Bruton's Tyrosine Kinase Inhibitor in Early Clinical Development.
AID1560797Inhibition of BTK in human B cells assessed as reduction in anti-IgM/IL4-stimulated CD69 expression on B cells preincubated for 60 mins followed by anti-IgM antibody/IL4 stimulation and measured after 16 hrs by flow cytometry2020Journal of medicinal chemistry, 05-28, Volume: 63, Issue:10
Discovery of LOU064 (Remibrutinib), a Potent and Highly Selective Covalent Inhibitor of Bruton's Tyrosine Kinase.
AID1560831Selectivity ratio of Kd for DNA-tagged recombinant TEC (unknown origin) to Kd for DNA-tagged recombinant BTK (unknown origin)2020Journal of medicinal chemistry, 05-28, Volume: 63, Issue:10
Discovery of LOU064 (Remibrutinib), a Potent and Highly Selective Covalent Inhibitor of Bruton's Tyrosine Kinase.
AID1560825Binding affinity to DNA-tagged recombinant ITK (unknown origin) measured after 1 hr by biotinylated-ligand affinity bead-based qPCR analysis2020Journal of medicinal chemistry, 05-28, Volume: 63, Issue:10
Discovery of LOU064 (Remibrutinib), a Potent and Highly Selective Covalent Inhibitor of Bruton's Tyrosine Kinase.
AID1809419Inhibition of Btk (unknown origin) assessed as ratio of Kinact/Ki2021Journal of medicinal chemistry, 09-09, Volume: 64, Issue:17
Discovery of the Bruton's Tyrosine Kinase Inhibitor Clinical Candidate TAK-020 (
AID1560833Selectivity ratio of Kd for DNA-tagged recombinant EGFR (unknown origin) to Kd for DNA-tagged recombinant BTK (unknown origin)2020Journal of medicinal chemistry, 05-28, Volume: 63, Issue:10
Discovery of LOU064 (Remibrutinib), a Potent and Highly Selective Covalent Inhibitor of Bruton's Tyrosine Kinase.
AID1468811Selectivity ratio of IC50 for cytoplasmic recombinant human full length His-tagged BMX to IC50 for recombinant human full length His-tagged BTK2018Journal of medicinal chemistry, 03-22, Volume: 61, Issue:6
Discovery of GDC-0853: A Potent, Selective, and Noncovalent Bruton's Tyrosine Kinase Inhibitor in Early Clinical Development.
AID1781976Cmax in ICR mouse at 15 mg/kg, po after 24 hrs2021Journal of medicinal chemistry, 11-11, Volume: 64, Issue:21
Discovery of 1-Amino-1
AID1880138Inhibition of EGFR (unknown origin)2022Journal of medicinal chemistry, 04-28, Volume: 65, Issue:8
The Ascension of Targeted Covalent Inhibitors.
AID1782001Selectivity index, ratio of IC50 for inhibition of ITK (unknown origin) to IC50 for inhibition of BTK (unknown origin)2021Journal of medicinal chemistry, 11-11, Volume: 64, Issue:21
Discovery of 1-Amino-1
AID1720509Inhibition of recombinant human GST-tagged EGFR (668 to 1210 residues) expressed in baculovirus expression system using Tyr 04 peptide as substrate preincubated for 1 hr by Z'-LYTE assay2020Bioorganic & medicinal chemistry letters, 07-15, Volume: 30, Issue:14
Discovery of quinoline-based irreversible BTK inhibitors.
AID1782016Antiproliferative activity against human Raji cells assessed as reduction in cell viability incubated for 72 hrs by celltiter-glo assay2021Journal of medicinal chemistry, 11-11, Volume: 64, Issue:21
Discovery of 1-Amino-1
AID1782002Selectivity index, ratio of IC50 for inhibition of EGFR (unknown origin) to IC50 for inhibition of BTK (unknown origin)2021Journal of medicinal chemistry, 11-11, Volume: 64, Issue:21
Discovery of 1-Amino-1
AID1468808Inhibition of recombinant human cytoplasmic GST-tagged LTK expressed in baculovirus at 1 uM by Z'-LYTE assay2018Journal of medicinal chemistry, 03-22, Volume: 61, Issue:6
Discovery of GDC-0853: A Potent, Selective, and Noncovalent Bruton's Tyrosine Kinase Inhibitor in Early Clinical Development.
AID1720523Inhibition of His-tagged recombinant full length human His-tagged BMX cytoplasmic domain expressed in baculovirus expression system using tyrosine-1 peptide as substrate preincubated for 1 hr in presence of ATP by Z'-LYTE assay2020Bioorganic & medicinal chemistry letters, 07-15, Volume: 30, Issue:14
Discovery of quinoline-based irreversible BTK inhibitors.
AID1468804Inhibition of human full length GST-tagged TXK expressed in baculovirus at 1 uM by Z'-LYTE assay2018Journal of medicinal chemistry, 03-22, Volume: 61, Issue:6
Discovery of GDC-0853: A Potent, Selective, and Noncovalent Bruton's Tyrosine Kinase Inhibitor in Early Clinical Development.
AID1720537In vivo inhibition of CD69 expression in po dosed mouse2020Bioorganic & medicinal chemistry letters, 07-15, Volume: 30, Issue:14
Discovery of quinoline-based irreversible BTK inhibitors.
AID1720522Inhibition of His-tagged recombinant human TEC expressed in baculovirus expression system preincubated for 1 hr by Z'lyte assay2020Bioorganic & medicinal chemistry letters, 07-15, Volume: 30, Issue:14
Discovery of quinoline-based irreversible BTK inhibitors.
AID1357747Inhibition of BTK (unknown origin)2018European journal of medicinal chemistry, May-10, Volume: 151The development of Bruton's tyrosine kinase (BTK) inhibitors from 2012 to 2017: A mini-review.
AID1878103Selectivity index, ratio of Kd for BLK (unknown origin) to Kd for BTK (unknown origin)2022Bioorganic & medicinal chemistry letters, 03-15, Volume: 60Optimization of a novel piperazinone series as potent selective peripheral covalent BTK inhibitors.
AID1880135Inhibition of BTK (unknown origin)2022Journal of medicinal chemistry, 04-28, Volume: 65, Issue:8
The Ascension of Targeted Covalent Inhibitors.
AID1880136Inhibition of TEC (unknown origin)2022Journal of medicinal chemistry, 04-28, Volume: 65, Issue:8
The Ascension of Targeted Covalent Inhibitors.
AID1720530Inhibition of EGFR phosphorylation in human A431 cells2020Bioorganic & medicinal chemistry letters, 07-15, Volume: 30, Issue:14
Discovery of quinoline-based irreversible BTK inhibitors.
AID1560881Covalent binding affinity to BTK in human blood assessed as reduction in biotinylated-probe binding at 300 nM measured up to 100 mins by immunoassay relative to control2020Journal of medicinal chemistry, 05-28, Volume: 63, Issue:10
Discovery of LOU064 (Remibrutinib), a Potent and Highly Selective Covalent Inhibitor of Bruton's Tyrosine Kinase.
AID1692287Inhibition of GP6 in human whole blood assessed as protein-mediated platelet aggregation preincubated for 15 mins followed by collagen stimulation and measured for 10 mins by multiple electrode aggregometry2020Journal of medicinal chemistry, 11-12, Volume: 63, Issue:21
Progress toward a Glycoprotein VI Modulator for the Treatment of Thrombosis.
AID1560822Binding affinity to DNA-tagged recombinant BTK (unknown origin) measured after 1 hr by biotinylated-ligand affinity bead-based qPCR analysis2020Journal of medicinal chemistry, 05-28, Volume: 63, Issue:10
Discovery of LOU064 (Remibrutinib), a Potent and Highly Selective Covalent Inhibitor of Bruton's Tyrosine Kinase.
AID1538771Inhibition of recombinant human GST-tagged EGFR cytoplasmic domain (668 to 1210 residues) expressed in baculovirus expression system using Z'-lyte-labelled tyr-4 peptide as substrate measured after 1 hr by FRET assay2019Journal of medicinal chemistry, 07-25, Volume: 62, Issue:14
Discovery of 4-Aminoquinoline-3-carboxamide Derivatives as Potent Reversible Bruton's Tyrosine Kinase Inhibitors for the Treatment of Rheumatoid Arthritis.
AID1468822Selectivity ratio of IC50 for recombinant human cytoplasmic GST-tagged ERBB4 to IC50 for recombinant human full length His-tagged BTK2018Journal of medicinal chemistry, 03-22, Volume: 61, Issue:6
Discovery of GDC-0853: A Potent, Selective, and Noncovalent Bruton's Tyrosine Kinase Inhibitor in Early Clinical Development.
AID1878120Binding affinity to JAK3 (unknown origin) assessed as dissociation constant by KINOMEscan analysis2022Bioorganic & medicinal chemistry letters, 03-15, Volume: 60Optimization of a novel piperazinone series as potent selective peripheral covalent BTK inhibitors.
AID1878116Binding affinity to BMX (unknown origin) assessed as dissociation constant by KINOMEscan analysis2022Bioorganic & medicinal chemistry letters, 03-15, Volume: 60Optimization of a novel piperazinone series as potent selective peripheral covalent BTK inhibitors.
AID1720538Inhibition of recombinant full length human His-tagged BLK cytoplasmic domain expressed in baculovirus expression system using tyrosine-1 peptide as substrate preincubated for 1 hr in presence of ATP by Z'-LYTE assay2020Bioorganic & medicinal chemistry letters, 07-15, Volume: 30, Issue:14
Discovery of quinoline-based irreversible BTK inhibitors.
AID1468805Inhibition of recombinant human full length His-tagged BLK expressed in baculovirus at 1 uM by Z'-LYTE assay2018Journal of medicinal chemistry, 03-22, Volume: 61, Issue:6
Discovery of GDC-0853: A Potent, Selective, and Noncovalent Bruton's Tyrosine Kinase Inhibitor in Early Clinical Development.
AID1878115Binding affinity to BLK (unknown origin) assessed as dissociation constant by KINOMEscan analysis2022Bioorganic & medicinal chemistry letters, 03-15, Volume: 60Optimization of a novel piperazinone series as potent selective peripheral covalent BTK inhibitors.
AID1878117Binding affinity to BTK (unknown origin) assessed as dissociation constant by KINOMEscan analysis2022Bioorganic & medicinal chemistry letters, 03-15, Volume: 60Optimization of a novel piperazinone series as potent selective peripheral covalent BTK inhibitors.
AID1878124Selectivity index, ratio of Kd for EGFR (unknown origin) to Kd for BTK (unknown origin)2022Bioorganic & medicinal chemistry letters, 03-15, Volume: 60Optimization of a novel piperazinone series as potent selective peripheral covalent BTK inhibitors.
AID1878129Selectivity index, ratio of Kd for TEC (unknown origin) to Kd for BTK (unknown origin)2022Bioorganic & medicinal chemistry letters, 03-15, Volume: 60Optimization of a novel piperazinone series as potent selective peripheral covalent BTK inhibitors.
AID1878118Binding affinity to EGFR (unknown origin) assessed as dissociation constant by KINOMEscan analysis2022Bioorganic & medicinal chemistry letters, 03-15, Volume: 60Optimization of a novel piperazinone series as potent selective peripheral covalent BTK inhibitors.
AID1560828Binding affinity to DNA-tagged recombinant ERBB4 (unknown origin) measured after 1 hr by biotinylated-ligand affinity bead-based qPCR analysis2020Journal of medicinal chemistry, 05-28, Volume: 63, Issue:10
Discovery of LOU064 (Remibrutinib), a Potent and Highly Selective Covalent Inhibitor of Bruton's Tyrosine Kinase.
AID1782037Antitumor activity against human TMD8 cells xenografted in CB-17 SCID nude mouse assessed as tumor growth inhibition at 7.5 mg/kg, po bid administered for 21 days2021Journal of medicinal chemistry, 11-11, Volume: 64, Issue:21
Discovery of 1-Amino-1
AID1781998Inhibition of full-length N-terminal GST-tagged ITK (2 to 620 residues) (unknown origin) expressed in Sf21 insect cells using NH2-ETVYSEVRK-biotin as substrate preincubated for 1 hr followed by ATP addition and measured after 2 hrs by ELISA2021Journal of medicinal chemistry, 11-11, Volume: 64, Issue:21
Discovery of 1-Amino-1
AID1720524Inhibition of recombinant full length human GST-tagged ITK expressed in baculovirus expression system using tyrosine-1 peptide as substrate preincubated for 1 hr in presence of ATP by Z'-LYTE assay2020Bioorganic & medicinal chemistry letters, 07-15, Volume: 30, Issue:14
Discovery of quinoline-based irreversible BTK inhibitors.
AID1560795Inhibition of full-length human recombinant BTK using FITC-Ahx-TSELKKVVALYDYMPMNAND-NH2 as substrate measured after 60 mins by caliper assay2020Journal of medicinal chemistry, 05-28, Volume: 63, Issue:10
Discovery of LOU064 (Remibrutinib), a Potent and Highly Selective Covalent Inhibitor of Bruton's Tyrosine Kinase.
AID1304232Inhibition of recombinant BTK (unknown origin) preincubated for 1 hr followed by ATP addition by IMAP assay2016Bioorganic & medicinal chemistry letters, 07-01, Volume: 26, Issue:13
Structure-based discovery of novel 4,5,6-trisubstituted pyrimidines as potent covalent Bruton's tyrosine kinase inhibitors.
AID1468764Inhibition of recombinant human cytoplasmic His-tagged ERBB2 expressed in baculovirus at 1 uM by Z'-LYTE assay2018Journal of medicinal chemistry, 03-22, Volume: 61, Issue:6
Discovery of GDC-0853: A Potent, Selective, and Noncovalent Bruton's Tyrosine Kinase Inhibitor in Early Clinical Development.
AID1468802Inhibition of recombinant human full length His-tagged BTK expressed in baculovirus at 1 uM by Z'-LYTE assay2018Journal of medicinal chemistry, 03-22, Volume: 61, Issue:6
Discovery of GDC-0853: A Potent, Selective, and Noncovalent Bruton's Tyrosine Kinase Inhibitor in Early Clinical Development.
AID1878127Selectivity index, ratio of Kd for ITK (unknown origin) to Kd for BTK (unknown origin)2022Bioorganic & medicinal chemistry letters, 03-15, Volume: 60Optimization of a novel piperazinone series as potent selective peripheral covalent BTK inhibitors.
AID1468810Inhibition of recombinant human cytoplasmic full length His-tagged TEC expressed in baculovirus at 1 uM by Z'-LYTE assay2018Journal of medicinal chemistry, 03-22, Volume: 61, Issue:6
Discovery of GDC-0853: A Potent, Selective, and Noncovalent Bruton's Tyrosine Kinase Inhibitor in Early Clinical Development.
AID1878128Selectivity index, ratio of Kd for JAK3 (unknown origin) to Kd for BTK (unknown origin)2022Bioorganic & medicinal chemistry letters, 03-15, Volume: 60Optimization of a novel piperazinone series as potent selective peripheral covalent BTK inhibitors.
AID1781997Inhibition of full-length N-terminal GST-tagged BMX (1 to 675 residues) (unknown origin) expressed in Sf21 insect cells using NH2-ETVYSEVRK-biotin as substrate preincubated for 1 hr followed by ATP addition and measured after 2 hrs by ELISA2021Journal of medicinal chemistry, 11-11, Volume: 64, Issue:21
Discovery of 1-Amino-1
AID1781999Inhibition of N-terminal DYKDDDD-tagged EGFR (669 to 1210 residues) (unknown origin) expressed in Sf21 insect cells using NH2-ETVYSEVRK-biotin as substrate preincubated for 1 hr followed by ATP addition and measured after 2 hrs by ELISA2021Journal of medicinal chemistry, 11-11, Volume: 64, Issue:21
Discovery of 1-Amino-1
AID1560835Selectivity ratio of Kd for DNA-tagged recombinant ERBB4 (unknown origin) to Kd for DNA-tagged recombinant BTK (unknown origin)2020Journal of medicinal chemistry, 05-28, Volume: 63, Issue:10
Discovery of LOU064 (Remibrutinib), a Potent and Highly Selective Covalent Inhibitor of Bruton's Tyrosine Kinase.
AID1468818Selectivity ratio of IC50 for recombinant human His-tagged catalytic RIPK2 to IC50 for recombinant human full length His-tagged BTK2018Journal of medicinal chemistry, 03-22, Volume: 61, Issue:6
Discovery of GDC-0853: A Potent, Selective, and Noncovalent Bruton's Tyrosine Kinase Inhibitor in Early Clinical Development.
AID1468806Inhibition of recombinant human catalytic GST-tagged JAK3 expressed in baculovirus at 1 uM by Z'-LYTE assay2018Journal of medicinal chemistry, 03-22, Volume: 61, Issue:6
Discovery of GDC-0853: A Potent, Selective, and Noncovalent Bruton's Tyrosine Kinase Inhibitor in Early Clinical Development.
AID1560836Selectivity ratio of Kd for DNA-tagged recombinant JAK3 (unknown origin) to Kd for DNA-tagged recombinant BTK (unknown origin)2020Journal of medicinal chemistry, 05-28, Volume: 63, Issue:10
Discovery of LOU064 (Remibrutinib), a Potent and Highly Selective Covalent Inhibitor of Bruton's Tyrosine Kinase.
AID1880139Inhibition of BTK in human whole blood2022Journal of medicinal chemistry, 04-28, Volume: 65, Issue:8
The Ascension of Targeted Covalent Inhibitors.
AID1468772Inhibition of BTK in human whole blood-derived CD19+ B cells assessed as suppression of anti-IgM stimulated-CD69 expression preincubated for 1 hr followed by IgM stimulation for 18 hrs by FACS analysis2018Journal of medicinal chemistry, 03-22, Volume: 61, Issue:6
Discovery of GDC-0853: A Potent, Selective, and Noncovalent Bruton's Tyrosine Kinase Inhibitor in Early Clinical Development.
AID1878123Selectivity index, ratio of Kd for BMX (unknown origin) to Kd for BTK (unknown origin)2022Bioorganic & medicinal chemistry letters, 03-15, Volume: 60Optimization of a novel piperazinone series as potent selective peripheral covalent BTK inhibitors.
AID1878121Binding affinity to TEC (unknown origin) assessed as dissociation constant by KINOMEscan analysis2022Bioorganic & medicinal chemistry letters, 03-15, Volume: 60Optimization of a novel piperazinone series as potent selective peripheral covalent BTK inhibitors.
AID1878125Selectivity index, ratio of Kd for ERBB2 (unknown origin) to Kd for BTK (unknown origin)2022Bioorganic & medicinal chemistry letters, 03-15, Volume: 60Optimization of a novel piperazinone series as potent selective peripheral covalent BTK inhibitors.
AID1878130Selectivity index, ratio of Kd for TXK (unknown origin) to Kd for BTK (unknown origin)2022Bioorganic & medicinal chemistry letters, 03-15, Volume: 60Optimization of a novel piperazinone series as potent selective peripheral covalent BTK inhibitors.
AID1560823Binding affinity to DNA-tagged recombinant BMX (unknown origin) measured after 1 hr by biotinylated-ligand affinity bead-based qPCR analysis2020Journal of medicinal chemistry, 05-28, Volume: 63, Issue:10
Discovery of LOU064 (Remibrutinib), a Potent and Highly Selective Covalent Inhibitor of Bruton's Tyrosine Kinase.
AID1782018Antiproliferative activity against human SUDHL2 cells assessed as reduction in cell viability incubated for 72 hrs by celltiter-glo assay2021Journal of medicinal chemistry, 11-11, Volume: 64, Issue:21
Discovery of 1-Amino-1
AID1560827Binding affinity to DNA-tagged recombinant ERBB2 (unknown origin) measured after 1 hr by biotinylated-ligand affinity bead-based qPCR analysis2020Journal of medicinal chemistry, 05-28, Volume: 63, Issue:10
Discovery of LOU064 (Remibrutinib), a Potent and Highly Selective Covalent Inhibitor of Bruton's Tyrosine Kinase.
AID1560824Binding affinity to DNA-tagged recombinant TEC (unknown origin) measured after 1 hr by biotinylated-ligand affinity bead-based qPCR analysis2020Journal of medicinal chemistry, 05-28, Volume: 63, Issue:10
Discovery of LOU064 (Remibrutinib), a Potent and Highly Selective Covalent Inhibitor of Bruton's Tyrosine Kinase.
AID1782013Antiproliferative activity against human MOLM-13 cells assessed as reduction in cell viability incubated for 72 hrs by celltiter-glo assay2021Journal of medicinal chemistry, 11-11, Volume: 64, Issue:21
Discovery of 1-Amino-1
AID1878104Binding affinity to ERBB4 (unknown origin) assessed as dissociation constant by KINOMEscan analysis2022Bioorganic & medicinal chemistry letters, 03-15, Volume: 60Optimization of a novel piperazinone series as potent selective peripheral covalent BTK inhibitors.
AID1782000Selectivity index, ratio of IC50 for inhibition of BMX (unknown origin) to IC50 for inhibition of BTK (unknown origin)2021Journal of medicinal chemistry, 11-11, Volume: 64, Issue:21
Discovery of 1-Amino-1
AID1782017Antiproliferative activity against human NAMALWA cells assessed as reduction in cell viability incubated for 72 hrs by celltiter-glo assay2021Journal of medicinal chemistry, 11-11, Volume: 64, Issue:21
Discovery of 1-Amino-1
AID1781996Inhibition of full-length N-terminal GST tagged BTK (2 to 659 residues) (unknown origin) expressed in Sf21 insect cells using NH2-ETVYSEVRK-biotin as substrate preincubated for 1 hr followed by ATP addition and measured after 2 hrs by ELISA2021Journal of medicinal chemistry, 11-11, Volume: 64, Issue:21
Discovery of 1-Amino-1
AID1468803Inhibition of cytoplasmic recombinant human full length His-tagged BMX expressed in baculovirus at 1 uM by Z'-LYTE assay2018Journal of medicinal chemistry, 03-22, Volume: 61, Issue:6
Discovery of GDC-0853: A Potent, Selective, and Noncovalent Bruton's Tyrosine Kinase Inhibitor in Early Clinical Development.
AID1560826Binding affinity to DNA-tagged recombinant EGFR (unknown origin) measured after 1 hr by biotinylated-ligand affinity bead-based qPCR analysis2020Journal of medicinal chemistry, 05-28, Volume: 63, Issue:10
Discovery of LOU064 (Remibrutinib), a Potent and Highly Selective Covalent Inhibitor of Bruton's Tyrosine Kinase.
AID1557598Inhibition of BTK (unknown origin)2019Journal of medicinal chemistry, 08-22, Volume: 62, Issue:16
Synthetic Approaches to the New Drugs Approved During 2017.
AID1720521Inhibition of His-tagged recombinant human His-tagged full length BTK expressed in baculovirus expression system using Tyr01 peptide as substrate preincubated for 1 hr by Z'lyte assay2020Bioorganic & medicinal chemistry letters, 07-15, Volume: 30, Issue:14
Discovery of quinoline-based irreversible BTK inhibitors.
AID1782019Antiproliferative activity against human Pfeiffer cells assessed as reduction in cell viability incubated for 72 hrs by celltiter-glo assay2021Journal of medicinal chemistry, 11-11, Volume: 64, Issue:21
Discovery of 1-Amino-1
AID1720526Inhibition of His-tagged human recombinant ERBB2 (676 to 1255 residues) expressed in baculovirus expression system using Tyr 06 as substrate preincubated for 1 hr in presence of ATP by Z'-LYTE assay2020Bioorganic & medicinal chemistry letters, 07-15, Volume: 30, Issue:14
Discovery of quinoline-based irreversible BTK inhibitors.
AID1878122Binding affinity to TXK (unknown origin) assessed as dissociation constant by KINOMEscan analysis2022Bioorganic & medicinal chemistry letters, 03-15, Volume: 60Optimization of a novel piperazinone series as potent selective peripheral covalent BTK inhibitors.
AID1468807Inhibition of recombinant human cytoplasmic GST-tagged EGFR expressed in baculovirus at 1 uM by Z'-LYTE assay2018Journal of medicinal chemistry, 03-22, Volume: 61, Issue:6
Discovery of GDC-0853: A Potent, Selective, and Noncovalent Bruton's Tyrosine Kinase Inhibitor in Early Clinical Development.
AID1560829Binding affinity to DNA-tagged recombinant JAK3 (unknown origin) measured after 1 hr by biotinylated-ligand affinity bead-based qPCR analysis2020Journal of medicinal chemistry, 05-28, Volume: 63, Issue:10
Discovery of LOU064 (Remibrutinib), a Potent and Highly Selective Covalent Inhibitor of Bruton's Tyrosine Kinase.
AID1782015Antiproliferative activity against human REC-1 cells assessed as reduction in cell viability incubated for 72 hrs by celltiter-glo assay2021Journal of medicinal chemistry, 11-11, Volume: 64, Issue:21
Discovery of 1-Amino-1
AID1560796Inhibition of BTK in vitamin D3 differentiated human THP1 cells assessed as inhibition of FCgammaR-induced IL8 production measured after 24 hrs by HTRF assay2020Journal of medicinal chemistry, 05-28, Volume: 63, Issue:10
Discovery of LOU064 (Remibrutinib), a Potent and Highly Selective Covalent Inhibitor of Bruton's Tyrosine Kinase.
AID1878126Selectivity index, ratio of Kd for ERBB4 (unknown origin) to Kd for BTK (unknown origin)2022Bioorganic & medicinal chemistry letters, 03-15, Volume: 60Optimization of a novel piperazinone series as potent selective peripheral covalent BTK inhibitors.
AID1560834Selectivity ratio of Kd for DNA-tagged recombinant ERBB2 (unknown origin) to Kd for DNA-tagged recombinant BTK (unknown origin)2020Journal of medicinal chemistry, 05-28, Volume: 63, Issue:10
Discovery of LOU064 (Remibrutinib), a Potent and Highly Selective Covalent Inhibitor of Bruton's Tyrosine Kinase.
AID1560882Inhibition of BTK in human basophils assessed as reduction in anti-IgE mouse IgG1 antibody Le2-stimulated CD63 expression on basophil preincubated for 30 mins in presence of IgE antibody B11 followed by anti-IgE mouse IgG1 antibody Le2 stimulation and mea2020Journal of medicinal chemistry, 05-28, Volume: 63, Issue:10
Discovery of LOU064 (Remibrutinib), a Potent and Highly Selective Covalent Inhibitor of Bruton's Tyrosine Kinase.
AID1853204Inhibition of BTK (unknown origin)2022RSC medicinal chemistry, Dec-14, Volume: 13, Issue:12
Advanced approaches of developing targeted covalent drugs.
AID1560832Selectivity ratio of Kd for DNA-tagged recombinant ITK (unknown origin) to Kd for DNA-tagged recombinant BTK (unknown origin)2020Journal of medicinal chemistry, 05-28, Volume: 63, Issue:10
Discovery of LOU064 (Remibrutinib), a Potent and Highly Selective Covalent Inhibitor of Bruton's Tyrosine Kinase.
AID1720527Inhibition of recombinant human N-terminal GST-tagged ERBB4 catalytic domain (708 to 993 residues) expressed in baculovirus expression system using tyrosine-1 peptide as substrate preincubated for 1 hr in presence of ATP by Z'-LYTE assay2020Bioorganic & medicinal chemistry letters, 07-15, Volume: 30, Issue:14
Discovery of quinoline-based irreversible BTK inhibitors.
AID1880140Inhibition of EGFR phosphorylation in human A-431 cells2022Journal of medicinal chemistry, 04-28, Volume: 65, Issue:8
The Ascension of Targeted Covalent Inhibitors.
AID1782014Antiproliferative activity against human TMD8 cells assessed as reduction in cell viability incubated for 72 hrs by celltiter-glo assay2021Journal of medicinal chemistry, 11-11, Volume: 64, Issue:21
Discovery of 1-Amino-1
AID1345572Human erb-b2 receptor tyrosine kinase 4 (Type I RTKs: ErbB (epidermal growth factor) receptor family)2016The New England journal of medicine, Jan-28, Volume: 374, Issue:4
Acalabrutinib (ACP-196) in Relapsed Chronic Lymphocytic Leukemia.
AID1345617Human Bruton tyrosine kinase (Tec family)2016The New England journal of medicine, Jan-28, Volume: 374, Issue:4
Acalabrutinib (ACP-196) in Relapsed Chronic Lymphocytic Leukemia.
AID1345502Human epidermal growth factor receptor (Type I RTKs: ErbB (epidermal growth factor) receptor family)2016The New England journal of medicine, Jan-28, Volume: 374, Issue:4
Acalabrutinib (ACP-196) in Relapsed Chronic Lymphocytic Leukemia.
AID1345705Human IL2 inducible T cell kinase (Tec family)2016The New England journal of medicine, Jan-28, Volume: 374, Issue:4
Acalabrutinib (ACP-196) in Relapsed Chronic Lymphocytic Leukemia.
AID1345860Human TXK tyrosine kinase (Tec family)2016The New England journal of medicine, Jan-28, Volume: 374, Issue:4
Acalabrutinib (ACP-196) in Relapsed Chronic Lymphocytic Leukemia.
AID1345682Human BLK proto-oncogene, Src family tyrosine kinase (Src family)2016The New England journal of medicine, Jan-28, Volume: 374, Issue:4
Acalabrutinib (ACP-196) in Relapsed Chronic Lymphocytic Leukemia.
AID1345744Human Janus kinase 3 (Janus kinase (JakA) family)2016The New England journal of medicine, Jan-28, Volume: 374, Issue:4
Acalabrutinib (ACP-196) in Relapsed Chronic Lymphocytic Leukemia.
AID1345882Human tec protein tyrosine kinase (Tec family)2016The New England journal of medicine, Jan-28, Volume: 374, Issue:4
Acalabrutinib (ACP-196) in Relapsed Chronic Lymphocytic Leukemia.
AID1345664Human BMX non-receptor tyrosine kinase (Tec family)2016The New England journal of medicine, Jan-28, Volume: 374, Issue:4
Acalabrutinib (ACP-196) in Relapsed Chronic Lymphocytic Leukemia.
AID1345653Human erb-b2 receptor tyrosine kinase 2 (Type I RTKs: ErbB (epidermal growth factor) receptor family)2016The New England journal of medicine, Jan-28, Volume: 374, Issue:4
Acalabrutinib (ACP-196) in Relapsed Chronic Lymphocytic Leukemia.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (209)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's56 (26.79)24.3611
2020's153 (73.21)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 31.69

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index31.69 (24.57)
Research Supply Index5.53 (2.92)
Research Growth Index4.81 (4.65)
Search Engine Demand Index39.83 (26.88)
Search Engine Supply Index1.91 (0.95)

This Compound (31.69)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials39 (18.31%)5.53%
Reviews50 (23.47%)6.00%
Case Studies9 (4.23%)4.05%
Observational1 (0.47%)0.25%
Other114 (53.52%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]